



No. 10-132362- -00004-0000

Fecha: 2011-10-14 09:54:44 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 400 OPOSIOBSERVTER Folios: 37

FORMULARIO ÚNICO DE OPOSICION

①

OPOSICIÓN A:

- | | |
|--|--|
| ☒ Patente de Invención. | ☐ Marca Colectiva. |
| ☐ Patente de Modelo de Utilidad. | ☐ Marca de Certificación. |
| ☐ Diseño Industrial. | ☐ Lema Comercial. |
| ☐ Esquema de Trazado para Circuitos Integrados. | |
| ☐ Marcas de Productos o Servicios. | |

②

SOLICITUD
PUBLICADA

Número del expediente: 10-132.362
Solicitante: DAIICHI SANKYO COMPANY LIMITED
Apoderado: LUZ CLEMENCIA SUAREZ DE PAEZ
Titulo de la nueva creacion o denominacion del signo: "DERIVADO DE
HIDROXI-QUINOXALIN-CARBOXAMIDA"
Gaceta: 630

③ OPOSICIÓN PRESENTADA POR:

SOLICITANTE	Nombre: <u>PROCAPS S.A.</u>	IDENTIFICACIÓN	
	Dirección: <u>CALLE 80 No. 78E-201</u> Nacionalidad o Domicilio: <u>COLOMBIA</u> Lugar de Constitución: <u>BAJOSANQUILLA</u> Teléfono: <u>371 99 00</u> Fax: <u>373 1313</u> E-mail: _____	C.C. ☐ NI ☒ C.E. ☐ Otro ☐ Cual _____ Número <u>990.136.527-5</u>	
REPRESENTANTE O APODERADO	Nombre: <u>ELIANA ISAUARA MORENO BOHORQUEZ</u> Dirección: <u>CARRERA 104 N°119-95 OF 104</u> Teléfono: <u>2131213</u> Fax: <u>6121979</u> E-mail: <u>negocios@optimum-co.com</u>	IDENTIFICACIÓN C.C. ☒ NI ☐ C.E. ☐ Otro ☐ Cual _____ Número <u>51.975.664</u> Tp <u>83823</u>	

④ FUNDAMENTOS DE LA OPOSICIÓN:

Causal: Art. 14, 16, 18, 20 y 30 de la Ley 486 de la CAN
No cumple con los requisitos de patentabilidad.

Signo opuesto: _____

Justificación:

La presente solicitud no cumple con los requisitos de patentabilidad dado que lo
revelado, ya se encontraba en el estado de la técnica o es posible derivarlo de la
misma tal y como se demostrará en el capítulo "Fundamento de Hecho".

⑤ Comprobante de pago No.

11-100 987

Fecha

18/10/2011

⑥ ANEXOS


- ☒ Comprobante de pago de la tasa.
- ☒ Poderes, si fuere el caso.
- ☒ Pruebas de los fundamentos de la oposición.
- ☐ Documentos que acrediten el legítimo interés, si fuere el caso.
- ☒ Documento que acredita la existencia y representación legal de las partes, cuando sean personas jurídicas.

⑦

NOMBRE:

ELIANA ISAURA MORENO BOHORQUEZ

FIRMA:



C.C. 51'975.664

TP. 83823

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

- / -



RECIBO DE CAJA

No. 11 - 100907

Bogotá D.C., Octubre 14 de 2011 - 09:13:17

RECIBIDO DE : PROCAPS S.A.

NI 890.106.527

*** Soporte del Pago ***

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR. PAGO
CONSIGNACION	BANCO DE BOGOTA	062754387	145108902	07/10/2011	2.128.000.00

*** Conceptos Pagados ***

CANT.	RENTISTICO	CONCEPTO	Vr. UNIDITARIO	Vr. CONCEPTO
1	50005-01-04 PRESENTACION DE OBSERVACIONES A SOLICITUDES	12 MARCAS Y LEMAS COMERCIALES	304.000.00	304.000.00
				\$304.000.00

SON: **TRESCIENTOS CUATRO MIL PESOS MONEDA CORRIENTE**

Responsable:

Recibo de Caja Aplicado al Expediente No.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 10-132362- -00004-0000

Fecha: 2011-10-14 09:54:44 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 400 OPOSIOBSERVTER Folios: 37

Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C.- Colombia

Web: www.sic.gov.co e-mai: info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

Octubre 14 de 2011 - 09:13:18

Señor Director,
DIRECCIÓN DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. S. D.

Referencia : Expediente N° 10 132362
Asunto : Oposición a la solicitud de patente de Invención titulada
"DERIVADO DE HIDROXI-QUINOXALIN-
CARBOXAMIDA"
Solicitante : DAIICHI SANKYO COMPANY LIMITED
Opositora : PROCAPS S.A.

Publicada en la Gaceta de la Propiedad Industrial
N° 630 del 21 de julio de 2011

Yo, *ELIANA ISaura MORENO BOHORQUEZ*, abogada en ejercicio, identificada como aparece al pie de su firma, con tarjeta profesional No. 83823 del Consejo Superior de la Judicatura, en mi condición de apoderada de la sociedad **PROCAPS** S.A. conformada bajo las leyes de la República de Colombia, atentamente manifiesto que estando dentro del término de ley y por orden expresa de mi representada, presento oposición a la concesión del registro de la Patente de Invención titulada "*DERIVADO DE HIDROXI-QUINOXALIN-CARBOXAMIDA*", cuyo titular es **DAIICHI SANKYO COMPANY LIMITED**, y pido a Usted declarar fundada esta oposición y en consecuencia negar el registro de la patente solicitada.



Derecho de la Competencia, Propiedad
Industrial y Comercio Exterior


1. INTERÉS PARA ACTUAR

Conforme a lo dispuesto en el artículo 42 de la Decisión 486 de 2000 de la CAN, estando dentro del término estipulado por la ley, manifiesto el legítimo interés de nuestra representada para oponerse al registro de la patente de la referencia, atendiendo a que la solicitud pretendida no cumple con los requisitos dispuestos en la ley como se analizará más adelante y de ser concedida afectaría directamente la comercialización de algunos productos de mi representada, que contienen, en particular ~~hidroxi~~ **quinoxalin-carboxamidas**. Por lo tanto, solicito respetuosamente a ese Despacho se sirva tener en cuenta la presente oposición dentro del trámite administrativo que se surte en esta Superintendencia.

2. FUNDAMENTOS DE HECHOS

2.1. La solicitud objeto de la presente fue presentada el 26 de octubre de 2010, reivindicando prioridad bajo la solicitud JP20080079919 del 2008-03-26; y fue publicada en Colombia, en la Gaceta de la Propiedad Industrial N° 630 del 21 de julio de 2011, cuya publicación internacional corresponde a la WO 2009119537 del 2009-10-01.

2.2. La solicitud colombiana 10 132362 objeto de la presente oposición, se refiere a un derivado de hidroxi quinoxalin-carboxamida que es útil para prevenir y/o tratar los trastornos de la coagulación sanguínea, más precisamente se refiere a un compuesto representado por la fórmula (I), o una sal farmacológicamente aceptable del mismo.



en donde cada uno de R1 y R2 representa independientemente un grupo tal como un átomo de hidrógeno o un átomo de halógeno; R3 representa un grupo tal como un átomo de hidrógeno; cada uno de R4 y R5 representa independientemente un grupo tal como un átomo de hidrógeno, un átomo de halógeno, o un grupo alquilo de 1 a 4 átomos de carbono; cada uno de R6 y R7 representa independientemente un átomo de hidrógeno o un grupo alquilo de 1 a 4 átomos de carbono; X representa un grupo tal como un grupo cicloalquilo de 3 a 10 átomos de carbono, un grupo arilo de 6 a 10 átomos de carbono, o un grupo heterocíclico de 5 a 10 miembros, el cual puede estar sustituido con los sustituyentes seleccionados a partir del grupo de sustituyentes a; Y representa un grupo tal como -CO-, -O- o -NRa-, y Ra representa un grupo tal como un átomo de hidrógeno o un grupo alquilo de 1 a 4 átomos de carbono.

2.3. En primera instancia, se debe advertir que las reivindicaciones se refieren a usos y no sólo a la composición farmacológica o a un método de fabricación mediante la cual se obtenga un producto tangible y según la legislación, decisión 486 de la Comunidad Andina de Naciones, Artículo 14.- “Los Países Miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento (...)”, los usos no están contemplados como patentables; y, Artículo 20.- “No serán patentables (...) d) los métodos terapéuticos o quirúrgicos para el tratamiento humano o animal, así como los métodos de diagnóstico aplicados a los seres humanos o a animales”. Solo serán


patentables los productos o procedimientos. Por lo tanto a luz de la norma, dicha materia referente al uso y a un método de tratamiento no sería patentable.

2.4. Ahora bien, con base en el artículo 14 de la Decisión 486 de la CAN consagra lo siguiente: *“Los países miembros otorgarán patentes para las invenciones, sean de producto o procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial”*. Así las cosas, las invenciones objeto de patente deben ser nuevas y tener nivel inventivo. Bien, pues antes de la fecha de prioridad de esta solicitud se encuentran los siguientes documentos que afecta la patentabilidad de la presente solicitud:

- D1: US 2007208056 publicada el 06 de septiembre de 2007.

2.5. Ahora bien, el documento D1, describe moduladores sustituidos de piperidinil de MIP-1 o CCR-1, de formula (I), estereoisómeros o sales farmacéuticamente aceptables de los mismos. Además, los métodos de tratamiento y prevención de las enfermedades inflamatorias como asma y enfermedades alérgicas, así como patologías autoinmunes como la artritis reumatoide y el rechazo de trasplante utilizando dichos moduladores. Dicho documento D1 revela adicionalmente un método para tratar un trastornos que comprende administrar a un paciente que lo necesita una cantidad terapéuticamente efectiva de al menos un compuesto de la invención, donde dicho trastorno se selecciona de la osteoartritis, aneurisma, fiebre, efectos cardiovasculares, la enfermedad de Crohn, insuficiencia cardíaca congestiva, enfermedades autoinmunes enfermedades, la infección por VIH, demencia asociada al VIH, la psoriasis, la fibrosis pulmonar idiopática, arteriosclerosis trasplante, física o químicamente inducida por trauma cerebral, enfermedad inflamatoria intestinal, alveolitis, colitis, lupus eritematoso sistémico,

nefritis suero nefrotóxico, glomerulonephritis, asma, múltiples esclerosis múltiple, arteriosclerosis, artritis reumatoide, restinosis, el trasplante de órganos, artritis psoriásica, mieloma múltiple, alergias, carcinoma hepatocelular, la osteoporosis, fibrosis renal y el cáncer.



2.6. Por lo tanto, este documento objeto de oposición a la luz del documento D1 carece evidentemente de ALTURA INVENTIVA.

2.7. En consecuencia y de acuerdo a lo descrito anteriormente, se deriva que la solicitud colombiana 10 132362 no puede pretender un monopolio por patente toda vez que lo que pretende no cumple con los tres requisitos necesarios para su protección.


2.8. Que por consiguiente, respecto a la solicitud pretendida se tiene que:

2.8.1. CARENCIA DE ALTURA INVENTIVA. Según la Decisión 486 de la Comunidad Andina de Naciones, Artículo 18.- "Se considerará que una invención tiene nivel inventivo, si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica.". A la fecha de prioridad, 26 de marzo de 2008, a partir del documento D1, un experto en la materia puede llegar de manera evidente a una composición farmacéutica como las de la solicitud objeto de la presente oposición, para la fabricación de un medicamento para el tratamiento de enfermedades relacionadas con problemas de trasplante de

6. NOTIFICACIONES

Para efectos de notificaciones que por disposición del artículo 50 del Decreto 01 de 1984 debe hacer su Despacho, informo que mi representada y la suscrita recibiremos notificaciones en la Secretaría de su Despacho o en mis oficinas situadas en la Carrera 13 N° 119-95, Of. 104 de esta ciudad de Bogotá.

Señor Superintendente,



ELIANA ISAURA MORENO BOHORQUEZ

C.C. 51'975.664 de Bogotá

T.P.A. 83823 del C.S. de la J.




PODER ESPECIAL

Yo, **WALTER TANAKA TATEKAWA**, mayor de edad y vecino de la ciudad de Barranquilla (Colombia), identificado como aparece al pie de mi firma, quien en el presente documento actúa en calidad de Representante Legal de la sociedad **PROCAPS S.A.** sociedad legalmente constituida y domiciliada en la ciudad de Barranquilla (Colombia), por el presente documento otorgo a la doctora **ELIANA ISAURA MORENO BOHORQUEZ**, abogada en ejercicio, identificada como aparece al pie de su firma, con tarjeta profesional No. 83823 del C.S. de la J., poder especial, amplio y suficiente, para formular oposiciones u observaciones a la solicitud de patente No. 10 132.362, titulada "**DERIVADO DE HIDROXI-QUINOXALIN-CARBOXAMIDA**", cuyo titular es **DAIICHI SANKYO COMPANY LIMITED**, publicada en la gaceta No. 630 del 21 de Julio de 2011.

Nuestro apoderado queda facultado, de manera expresa, para realizar todo tipo de actos necesarios para llevar a cabo el trámite de la oposición, incluyendo, sin limitación, preparar y presentar solicitudes, hacer declaraciones, pagar tasas, contribuciones e impuestos, recabar los títulos o certificados. Asimismo quedan autorizados para impugnar administrativamente todo lo que fuere resuelto en el expediente a que se hace expresa referencia en el presente poder, con todas las facultades generales y específicas que fuera requerido para ella.

De la misma manera, además de las facultades que le confiere la naturaleza del presente mandato, se encuentran facultados para recibir, desistir, transigir, sustituir, y reasumir el presente poder, incoar acciones, interponer recursos y demás facultades conferidas por la ley.


Dado y Firmado en Barranquilla (Colombia) a los 29 días del mes de Septiembre de 2011.

PROCAPS S.A.


C.C. N° 16'251.923
 NIT: 890.106.527-5
 Representante Legal

APROBADO
 29 SEP 2011
PROCAPS S.A.

NOTARIA
3^{era} NOTARIA TERCERA DEL CIRCULO DE BARRANQUILLA
DILIGENCIA DE RECONOCIMIENTO
Ante el Notario Tercero de Barranquilla se presento:
Walter Tancara Totekano
identificado con: Ce: 16251923 palma
Y declaro que el contenido del anterior Documento es cierto
y suya la firma que lo retendra.
Barranquilla: 30 SET. 2011





***** Pag. 1

CAMARA DE COMERCIO
DE BARRANQUILLA

13*****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----

NIT: 890.106.527-5.

EL SUSCRITO SECRETARIO DE LA CAMARA DE COMERCIO DE BARRANQUILLA, CON FUNDAMENTO EN LAS INSCRIPCIONES DEL REGISTRO MERCANTIL:

C E R T I F I C A

Que por Escritura Pública No. 1,190 del 22 de Julio de 1976, otorgada en la Notaria Tercera de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 28 de Julio de 1976 bajo el No. 6,070 del libro respectivo, fue constituida la sociedad-----
 limitada denominada "PRODUCTORA DE CAPSULAS DE GELATINAS LIMITADA
 "PROCAPS LIMITADA".-----

C E R T I F I C A

Que por Escritura Pública No. 1,307 del 28 de Junio de 1979, otorgada en la Notaria Tercera de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 23 de Julio de 1979 bajo el No. 10,039 del libro respectivo, la sociedad antes mencionada-----
 se transformo en sociedad anonima bajo la denominacion social de
 "PRODUCTORA DE CAPSULAS DE GELATINA S.A." PROCAPS S.A.".-----

C E R T I F I C A

Que por Escritura Pública No. 3,810 del 31 de Dic/bre de 1980, otorgada en la Notaria Primera de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 30 de Enero de 1981 bajo el No. 12,705 del libro respectivo, la sociedad antes mencionada-----
 se transformo en sociedad de responsabilidad limitada bajo al razon social de "PRODUCTORA DE CAPSULAS DE GELATINA LIMITADA "PROCAPS LI -
 MITADA".-----

C E R T I F I C A

Que por Escritura Pública No. 3,755 del 10 de Nov/bre de 1983, otorgada en la Notaria Unica de Soledad, inscrito(as) en esta Cámara de Comercio, el 22 de Nov/bre de 1983 bajo el No. 17,922 del libro respectivo, la sociedad antes mencionada-----
 se transformo en sociedad anonima bajo la denominacion social de
 "PRODUCTORA DE CAPSULAS DE GELATINA S.A." PROCAPS S.A.".-----

C E R T I F I C A

Que por Escritura Pública No. 3,615 del 06 de Dic/bre de 1996, otorgada en la Notaria 2a. de Barranquilla, inscrito(as) en esta Cámara de Comercio, el 20 de Dic/bre de 1996 bajo el No. 67,218 del

***** C O N T I N U A *****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----
NIT: 890.106.527-5.

libro respectivo, la sociedad antes mencionada-----
cambio de razon social, por la denominacion LABORATORIOS PROCAPS S.A.

C E R T I F I C A

Que por Escritura Pública No. 3,775 del 18 de Dic/bre de 1996,
otorgada en la Notaria 2a. de Barranquilla, inscrito(as) en esta
Cámara de Comercio, el 23 de Enero de 1997 bajo el No. 67,704 del
libro respectivo, la sociedad antes mencionada-----
cambio de razon social, por la denominacion PROCAPS S.A. -----

C E R T I F I C A

Que dicha sociedad ha sido reformada por las siguientes escrituras
y/o documentos privados:

Numero	aaaa/mm/dd	Notaria	No. Insc o Reg	aaaa/mm/dd
39	1979/01/18	Notaria 3a. de Barranquilla.	9,452	1979/01/24
992	1981/04/30	Notaria 1a. de Barranquilla.	13,112	1981/05/06
1,464	1982/08/27	Notaria Unica de Soledad	15,533	1982/09/08
2,744	1983/08/18	Notaria Unica de Soledad	17,416	1983/08/26
3,826	1984/07/16	Notaria Unica de Soledad	19,554	1984/07/27
3,835	1985/08/26	Notaria Unica de Soledad	22,230	1985/09/04
2,260	1986/09/10	Notaria Unica de Soledad.	24,995	1986/09/15
1,849	1989/07/11	Notaria 2a. de Barranquilla.	33,909	1989/07/13
444	1990/02/21	Notaria 2a. de Barranquilla.	36,101	1990/03/16
3,090	1991/12/17	Notaria 2a. de Barranquilla.	43,993	1992/01/28
269	1993/02/01	Notaria 2a. de Barranquilla.	48,428	1993/02/16
2,342	1993/07/28	Notaria 2a. de Barranquilla.	50,582	1993/08/10
3,652	1993/11/09	Notaria 2a. de Barranquilla	51,798	1993/11/22
3,615	1996/12/06	Notaria 2a. de Barranquilla	67,218	1996/12/20
89	1997/01/16	Notaria 2a. de Barranquilla	67,704	1997/01/23
2,070	1997/07/17	Notaria 2a. de Barranquilla	70,627	1997/07/31
2,281	1997/08/04	Notaria 2a. de Barranquilla	70,813	1997/08/14
765	1999/04/22	Notaria 3a. de Barranquilla	80,628	1999/04/23
459	2001/02/21	Notaria 2a. de Barranquilla	91,502	2001/02/23
2,608	2001/10/05	Notaria 2a. de Barranquilla	95,771	2001/11/08
1,730	2004/07/29	Notaria 2. de Barranquilla	112,999	2004/08/26
416	2005/03/03	Notaria 2. de Barranquilla	116,364	2005/03/10
1,613	2005/07/28	Notaria 2. de Barranquilla	119,322	2005/08/18
710	2009/05/05	Notaria 3 a. de Barranquilla	150,130	2009/06/30
1,054	2009/06/25	Notaria 3 a. de Barranquilla	150,130	2009/06/30

C E R T I F I C A

Que de acuerdo con la(s) escritura(s) arriba citada(s), la sociedad
se rige por las siguientes disposiciones:

DENOMINACION O RAZON SOCIAL:

PROCAPS S.A.-----

SIGLA: PROCAPS.

DOMICILIO PRINCIPAL: Barranquilla.

NIT No: 890.106.527-5.

MATRICULA MERCANTIL: 24,802.

***** C O N T I N U A *****



***** Pag. 2
 CAMARA DE COMERCIO
 DE BARRANQUILLA
 13*****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----

NIT: 890.106.527-5.

C E R T I F I C A

Direccion para notificaciones judiciales:

CL 80 No 78 B - 201.

De la ciudad de Barranquilla.

Correo electrónico:

mlozada@procaps.com.co

Pagina Web:

Teléfono:

3719272

C E R T I F I C A

DURACION: Que la sociedad no se halla disuelta y su término de duración se fijó hasta el 18 de Agosto de 2073.

C E R T I F I C A

OBJETO SOCIAL: El objeto principal de la sociedad sera: a) La fabricacion, importacion y comercializacion de alimentos procesados y suplementos dietarios. b) La fabricacion de capsulas y otros productos similares a partir de materiales tales como gelatinas u otros de distinta naturaleza, que puedan ser utilizados como envases o recipientes de productos y sustancias quimicas, farmaceuticas, alimenticias y cosmeticas, para uso y consumo humano y veterinario. c) La investigacion, desarrollo y fabricacion de toda clase de productos y sustancias quimicas, farmaceuticas, alimenticias y cosmeticas para uso y consumo humano, animal y vegetal. d) La compra y venta de materias primas, insumos y productos intermedios necesarios para los procesos de fabricacion de sustancias quimicas, farmaceuticas, alimenticias y cosmeticas, asi como la comercializacion interna y externa de los productos terminados. e) La compra, venta, importacion, exportacion y distribucion de toda clase de elementos instrumentales y equipos medicos, quirurgicos, odontologicos y hospitalarios para la salud humana y animal. f) La compra, venta, exportacion, fabricacion, importacion, distribucion de dulces, confites, galletas y todo tipo de golosinas o alimentos para el consumo humano. g) Actuar como representante o agente de personas naturales y juridicas, nacionales y extranjeras en la realizacion de operaciones o transacciones relacionadas con la industria farmaceutica y en especial con cualquiera de las actividades descritas en los literales a), b), c), d) y e) antes descritos. h) Prestar los servicios de asesorias y consultoria en las areas administrativas, de mercadeo, analisis clinico, asistencia tecnica, investigacion,

***** C O N T I N U A *****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.

NIT: 890.106.527-5.

costos y produccion, exportaciones, importaciones, ventas, relacionadas con iguales o similares actividades a las que constituyen el objeto de PROCAPS S.A.; asi como los de publicidad y promocion de productos quimicos, alimenticios, cosmeticos y farmaceuticos para uso humano, animal o industrial. i) Adquirir, operar, administrar y explotar, a cualquier titulo, empresa o establecimientos dedicados a la investigacion, desarrollo, fabricacion o comercializacion de productos quimicos, farmaceuticos, alimenticios, hospitalarios o cosmeticos. En desarrollo de su objeto principal, la sociedad podra tomar interes social como accionista, socio o fundador de empresas que tengan igual o similar objeto, comprar, vender, importar y exportar maquinarias, insumos y repuestos requeridos para el desarrollo de sus actividades; tomar dinero en prestamo, financiar y garantizar las operaciones comerciales que celebre con terceros relativas a su objeto; celebrar y ejecutar todo tipo de actos y contratos necesarios para desarrollar sus operaciones; girar, aceptar, otorgar y protestar todo tipo de titulos valores e instrumentos negociables, comprar, vender y constituir gravámenes sobre bienes muebles e inmuebles, designar representantes apoderados en el pais y en el exterior y, en general, realizar cualquier acto o negocio que sea necesario o conveniente para el desarrollo de su objeto social y para la mejor proteccion de sus intereses corporativos o la de sus socios. La sociedad podra garantizar el cumplimiento de sus obligaciones adquiridas por terceros o por sus socios, para lo cual podra inclusive constituir gravámenes reales sobre sus bienes de cualquier naturaleza.

C E R T I F I C A

CAPITAL	Nro Acciones	Valor Acción
Autorizado		
\$*****2,000,000,000	*****2,000,000	*****1,000
Suscrito		
\$*****1,298,000,000	*****1,298,000	*****1,000
Pagado		
\$*****1,298,000,000	*****1,298,000	*****1,000

C E R T I F I C A

ADMINISTRACION: La direccion y administracion de la sociedad correspondera a la Asamblea General de Accionistas, a la Junta Directiva, al Presidente, al Vicepresidente y a un Gerente General. Corresponde a la Junta Directiva las siguientes funciones y atribuciones entre otras: Autorizar cualquier acto o contrato cuya cuantia sea superior al equivalente en pesos Colombianos a doscientos cincuenta mil dolares de los Estados Unidos de America (US\$250.000), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la transacion. Cuando se trate de operaciones en virtud de las cuales la sociedad garantice obligaciones de terceros o de los socios, se requerira que la operacion sea aprobada con el voto de por lo menos 2/3 partes de los integrantes de la Junta Directiva. La sociedad tendra un Presidente, quien ejercera la representa-

***** C O N T I N U A *****



***** Pag. 3

CAMARA DE COMERCIO
DE BARRANQUILLA

13*****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----

NIT: 890.106.527-5.

cion legal de la sociedad y tendra las siguientes atribuciones entre otras: Ejecutar las decisiones de la Asamblea General de Accionistas y de la Junta Directiva. Ejercer la Representacion Legal de la sociedad en todos los actos y contratos que se requieran para el desarrollo del objeto social, de conformidad con lo previsto en las leyes y en los presentes estatutos. Constituir apoderados judiciales y extrajudiciales, recibir notificaciones, absolver interrogatorios de parte, confesar obligaciones de la sociedad, transigir, disistir y allanar a la sociedad en cualquier asunto judicial. Aprobar y celebrar en nombre de la socieda todo acto o contrato cuya cuantia sea igual o inferior al equivalente en pesos colombianos a doscientos cincuenta mil dolares de los Estados Unidos de America (US\$250.000), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la transacion o celebracion del acto. Las demas funciones que le correspondan como Representante Legal por disposicion de la ley, de estos estatutos o de la Junta Directiva. El Presidente tendra un suplente, designado por la Junta Directiva, quien reemplazara al Presidente en sus faltas temporales, absolutas o meramente accidentales, con entidades facultades y sin que sea necesario para ello acreditar la ausencia del principal. La sociedad tendra un Vicepresidente designado por la Junta Directiva, quien tambien ejercera la representacion legal de la sociedad, pudiendo ejercerla conjunta o separadamente con el Presidente. El vicepresidente tendra las siguientes facultades entre otras. Ejecutar dentro de su competencia las decisiones de la Asamblea General de Accionistas, de la Junta Directiva y del Presidente. Ejercer la representacion legal de la sociedad en todos los actos y contratos que se requieran para el desarrollo del objeto social, de conformidad con lo previsto en las leyes y en los presentes estatutos. Constituir apoderados judiciales y extrajudiciales, recibir notificaciones, absolver interrogatorios de parte, confesar obligaciones de la sociedad, transigir, desistir y allanar a la sociedad en cualquier asunto judicial. Aprobar y celebrar en nombre de la sociedad todo acto o contrato cuya cuantia sea igual o inferior al equivalente en pesos colombianos a ciento cincuenta mil dolares de los Estados Unidos de America (US\$150.000), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la aprobacion o celebracion del acto, siempre que no se trate de enajenar bienes inmuebles o cualquier otro activo fijo de la sociedad, inclusive de naturaleza muebles, acciones, cuotas o partes de interes inversiones y todo tipo de derechos de la sociedad, o de constituir gravámenes sobre cualquiera de los anteriores, facultades que radican exclusiva y privativamente en cabeza del Presidente. Las demas funciones que le corresponda como Representante legal por disposicion de la ley, de estos estatutos

***** C O N T I N U A *****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----
NIT: 890.106.527-5.

o de la Junta Directiva. El Vicepresidente tendra (1) suplente, designado por la Junta Directiva, quien lo reemplazara conjunta o separadamente en sus faltas temporales, absolutas o meramente accidentales, con identicas facultades y sin que sea necesario para ello acreditar la ausencia del principal. La sociedad tendra un (1) Gerente General, con su respectivo Suplente, designados por la Junta Directiva. El Suplente reemplazara al Gerente General, en sus faltas temporales, absolutas o meramente accidentales, quien junto con el gerente general, llevaran la representacion legal de la sociedad, con identicas facultades, pudiendolas ejercer conjunta o separadamente con el Presidente y Vicepresidente, con identicas facultades que el Gerente General y sin que sea necesario para ello acreditar la ausencia del titular. El Gerente General tendra las siguientes facultades entre otras: Ejercer la representacion legal de la sociedad, en todos los actos y contratos que se requieran para el desarrollo del objeto social, de conformidad con lo previsto en las leyes y en los presentes estatutos. Aprobar y celebrar en nombre de la sociedad todo acto o contrato cuya cuantia sea igual o inferior al equivalente en pesos Colombianos a Cincuenta Mil dolares de los Estados Unidos de America (US\$50.000), liquidados a la tasa de cambio representativa del mercado vigente el dia en que se surta la aprobacion o celebracion del acto, siempre que no se trate de enajenar a cualquier titulo bienes inmuebles o cualquier otro activo fijo de la sociedad, inclusive de naturaleza mueble, acciones, cuotas o partes de interes, inversiones y todo tipo de derechos de la sociedad o de constituir gravámenes sobre cualquiera de las anteriores facultades que radican exclusiva y privativamente en cabeza del Presidente.

C E R T I F I C A

Que según Acta No. 116 del 27 de Junio de 1997 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad:

PROCAPS S.A.-----
cuya parte pertinente se inscribió en esta Cámara de Comercio, el 15 de Agosto de 1997 bajo el No. 70,838 del libro respectivo, y según Acta No. 127 del 22 de Marzo de 2000 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad:

PROCAPS S.A.-----
cuya parte pertinente se inscribió en esta Cámara de Comercio, el 29 de Mayo de 2000 bajo el No. 87,250 del libro respectivo, fueron hechos los siguientes nombramientos:

CLASE: JUNTA DIRECTIVA

Principales

1. Minski Gontovnik Ruben	CC.*****7,463,982
2. Minski Gontovnik Meyer	CC.*****7,461,324
3. Minski Gontovnik Jose	CC.*****8,671,834

Suplentes

1. Minski Zirberblum Elliot	CC.*****72,219,541
2. Minski Deitel Daniel	*****

***** C O N T I N U A *****



***** Pag. 4

CAMARA DE COMERCIO
DE BARRANQUILLA

13*****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----

NIT: 890.106.527-5.

3. Minski Sharon

PA.*990,212,082,805

C E R T I F I C A

Que según Acta No. 116 del 27 de Junio de 1997 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 15 de Agosto de 1997 bajo el No. 70,838 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Presidente.	
Minski Gontovnik Ruben	CC.******7,463,982
Suplente del Presidente	
Minski Minski Abraham	CC.******802,575
Vicepresidente	
Minski Gontovnik Meyer	CC.******7,461,324
Suplente del vicepresidente	
Minski Gontovnik Jose	CC.******8,671,834

C E R T I F I C A

Que según Acta No. 11 del 01 de Febrero de 2001 correspondiente a la Junta Directiva en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 12 de Febrero de 2001 bajo el No. 91,273 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Gerente General.	
Uribe Ochoa Guillermo Luis	CC.******70,073,754

C E R T I F I C A

Que según Acta No. 406 del 02 de Sep/bre de 2004 correspondiente a la Junta Directiva en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 09 de Sep/bre de 2004 bajo el No. 113,263 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Suplente del Gerente.	
Tanaka Tatekawa Walter	CC.******16,251,923

C E R T I F I C A

Que según Acta No. 124 del 29 de Marzo de 1999 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad: PROCAPS

***** C O N T I N U A *****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A. -----
NIT: 890.106.527-5.

S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 04 de Agosto de 1999 bajo el No. 82,226 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Revisor Fiscal Ppal. Vargas Pertuz Ana Isabel	CC.*****32,696,645

C E R T I F I C A

Que según Acta No. 158 del 17 de Junio de 2011 correspondiente a la Asamblea de Accionistas en Barranquilla, de la sociedad: PROCAPS S.A. cuya parte pertinente se inscribió en esta Cámara de Comercio, el 23 de Junio de 2011 bajo el No. 170,929 del libro respectivo, fueron hechos los siguientes nombramientos:

Cargo/Nombre	Identificación
Revisor Fiscal Suplente Rodriguez Rey Jose Luis	CC.*****72,001,912

C E R T I F I C A

Que por Escritura Pública No. 2,784 del 07 de Dic/bre de 2007, otorgada en la Notaria 2ª de Barranquilla cuya parte pertinente se inscribió en esta Cámara de Comercio, el 20 de Dic/bre de 2007 bajo el No. 3,492 del libro respectivo, -----

y las inscripciones 3.492-1, 3.493, 3.494, 3.495, 3.496, 3.497, ----
3.498, 3.499, 3.500, 3.501, 3.502, 3.503, 3.504, 3.505, 3.506, ----
3.507, Consta que RUBEN MINSKI GONTOVNIK, C.C. No. 7.463.982, -----
obrando como Presidente y Representante Legal de la sociedad C.I.
NATURMEGA S.A., que obrando en su condición de Presidente y -----
Representante Legaql de la sociedad PROCAPS S.A., el presidente ----
debidamente facultado por los Estatutos Sociales y por el Maximo
Organo Social, otorga los siguientes poderes: Otorgar poder -----
general, amplio y suficiente a los doctores JOSEFINA DEL CARMEN ----
MIELES BUELVAS CC.No.33.138.497; a MARCELA CARVAJALINO PAGANO -----
CC.No.22.579.748; CRISTINA VIOLI FRANCESCHINI CC.No.22.463.716, con
las facultades que se transcriben a continuación: a.- Para que ----
representen a la sociedad PROCAPS S.A, ante todo tipo de -----
autoridades administrativas y jurisdiccionales, en asuntos de -----
naturaleza civil, laboral, comercial, penal, aduanera, cambiaria,
tributaria, policiva, administrativa y fiscal. b.- Contestar y ----
presentar demandas, requerimientos, recursos, pedir y aportar -----
pruebas, recibir, notificarse, ejercer la accion de tutela, -----
tramitar incidente de desacato, comparecer en los procesos que ----
cursen contra la sociedad, allanarse en nombre de la sociedad en
los asuntos que sean necesarios, transigir, desistir, sustituir,
renunciar y reasumir el poder. c.- La facultad expresa de -----
conciliar, por tanto pueden llegar a acuerdos conciliatorios, ----
transaccionales, judiciales o extrajudiciales o extrajudiciales,
cualquiera que sea su cuantía, para lo cual las apoderadas deben
aportar la autorizacion simple y escrita del Representante legal
de la sociedad. d.- Podran presentar solicitudes de devolucion y/o
compensacion de impuestos, ventas y rentas, recibir los pagos por
las devoluciones y adelantar todo tramite o proceso administrativo

***** C O N T I N U A *****



***** Pag. 5
 C A M A R A D E C O M E R C I O
 D E B A R R A N Q U I L L A
 13*****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----
 NIT: 890.106.527-5.

ante la DIAN, de tal forma que en ningun momento quede sin -----
 representacion legal de la sociedad. PODERES ESPECIALES: a.- Se ----
 confiere poder especial amplio y suficiente a las personas que se ----
 determinan seguidamente, que conforman el grupo A y B, para, para
 que conjuntamente suscriban contratos de suministros de mercancías
 y servicios con entidades oficiales, hasta la suma de OCHOCIENTOS
 MIL DOLARES DE LOS ESTADOS UNIDOS DE AMERICA (US800.000.00), -----
 liquidados a la tasa representativa del mercado vigente en el día
 que se realice la respectiva transaccion. Grupo A. WALTER NANAKA
 TATEKAWA CC.No.16.251.923, CLAUDIA TANGARIFE CASTILLO -----
 CC.No.41.660.293, CARMEN ALICIA FLOREZ CC.No.22.434.044, IVAN -----
 VILLAREAL CAMACHO CC.No.91.201.749, CARMEN ALICIA HERRERA -----
 DIAZGRANADOS CC.No.22.377.540, DAVID ANTONIO CHARRIS GIRALDO -----
 CC.No.19.341.274, RICARDO DORADO HURTADO CC.No.79.715.772, JAIME
 FORERO LLINAS CC.No.19.300.593. b.- Se confiere poder especial ----
 amplio y suficiente al señor WILLIAM ALBERTO BARROS CERRA -----
 CC.No.8.715.941, para que en nombre y representacion de PROCAPS ----
 S.A., suscriban declaraciones cambiarias, aduaneras y tributarias a
 que este obligada la sociedad, en el giro normal de sus negocios y
 operaciones sociales, por tanto quedan facultados para firmarlas,
 como tambien los demas documentos relacionados con ellas, -----
 notificarse, aportar y solicitar las pruebas que sean necesarias.
 c.- Otorgar poder especial amplio y suficiente al señor MARLON ----
 TATIS PAREDES CC.No.72.176.874 y al señor WILLIAM ALBERTO BARROS
 CERRA CC.No.8.715.941, para que en nombre y representacion de -----
 PROCANPS S.A., suscriban las declaraciones, reportes y cualquier
 documento relacionado con los tramites o registros de Comercio ----
 Exterior y o cualquier entidad del Estado que haga sus veces: d)
 Otorgar poder especial amplio y suficiente a la doctora CARMEN ----
 ALICIA HERRERA DIAZGRANADOS, CC.No.22.377.540 y al doctor WALTER
 TANAKA TATEKAWA, CC.No.16.251.923, para que en nombre y -----
 representacion de PROCAPS S.A.; endosen los titulos valores de la
 sociedad hasta por la suma de UN MIL MILLONES DE PESOS -----
 (1.000.000.000.00) M.L. CUARTO: EI representante legal de la -----
 sociedad PROCAPS S.A.; doctor RUBEN MINSKI GONTOVNIK, manifiesta
 que la presente reforma fue aprobada por la Asamblea General -----
 Extraordinaria de Accionista de PROCAPS S.A., con observancia de
 las disposiciones legales y estatutarias.-----

C E R T I F I C A

Que por Escritura Pública No. 1,933 del 16 de Sep/bre de 2008,
 otorgada en la Notaria 2 a. de Barranquilla cuya parte pertinente
 se inscribió en esta Cámara de Comercio, el 06 de Octubre de 2008
 bajo el No. 3,748 del libro respectivo,-----

***** C O N T I N U A *****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----
NIT: 890.106.527-5.

Consta que el señor RUBEN MINSKI GONTOVNIK, C.C. No. 7.463.982, que comparece en su condicion de Presidente y Representante Legal de la Sociedad PROCAPS S.A., confiere por medio de este instrumento ----- publico Poder especial Amplio y Suficiente a la doctora MILENA ----- ESCAFFI PARDO, C.C. No. 32.758.420, para que en nombre y ----- representacion de PROCAPS S.A., suscriba declaraciones cambiarias, aduaneras y tributarias a que este obligada la sociedad en el giro normal de sus negocios y operaciones sociales, por tanto queda ----- facultada para firmar, como tambien los demas documentos ----- relacionados con ellas, notificarse, aportar y solicitar las ----- pruebas que sean necesarias.-----

C E R T I F I C A

Que por Documento Privado del 09 de Abril de 2010, otorgado en Barranquilla inscrito en esta Cámara de Comercio, el 20 de Abril de 2010 bajo el Nro 4,201 del libro respectivo,-----
Consta que el señor RUBEN MINSKI GONTOVNIK, C.C. No. 7.463.982, ---- quien obra en el caracter de Presidente y/o Representante legal de la sociedad PROCAPS S.A., que por medio de este instrumento ----- publico, otorga Poder Especial Amplio y Suficiente a la Doctora ---- MONICA DE HART DE OCHOA, identificada con C.C. No. 32.676.025, para que en nombre y representacion de la sociedad, Endose las Facturas Nacionales e Internacionales hasta por la suma de UN MIL MILLONES DE PESOS (\$1.000.000.000.00)M.L. La doctora, Mónica de Hart de Ochoa, queda facultada para realizar todo acto o tramite necesario para el cabal cumplimiento del presente mandato.-----

C E R T I F I C A

Que por Documento Privado del 10 de Junio de 2010, otorgado en Barranquilla inscrito en esta Cámara de Comercio, el 13 de Julio de 2010 bajo el Nro 4,228 del libro respectivo,-----
consta que el señor RUBEN MISNKI GONTOVNIK, cc. No. 7.463.982 en su condicion de Presidente y representante legal de PROCAPS S.A., ---- confiere poder especial, amplio y suficiente al señor RICARDO DORADO HURTADO cc. No. 79.715.772 para que represente a la sociedad, ante el INVIMA, Fondo Nnacional de estupefacientes e ICA, con el fin que gestione, tramite o presente las diferentes solicitudes y ----- peticiones de la empresa, segun la competencia de estas entidades.
Por lo anterior, el Señor RICARDO DORADO HURTADO, queda facultado para presentar, gestionar, tramitar y firmar las diferentes ----- solicitudes y peticiones de la empresa, segun la competencia de ---- estas entidades, como tambien presentar y firmar todo los ----- documentos relacionados con estas solicitudes, notificarse de ----- cualquier acto administrativo que expidan, aportar y solicitar las pruebas que sean necesarias, desistir, y en general a realizar todo tramite o acto necesario de tal forma que la sociedad en ningun ---- momento quede sin representacion legal ante estas entidades, en ---- cumplimiento fiel al mandato otorgado.-----

C E R T I F I C A

***** C O N T I N U A *****



***** Pag. 6

C A M A R A D E C O M E R C I O
D E B A R R A N Q U I L L A

13*****

CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.-----

NIT: 890.106.527-5.

Que por Documento Privado del 03 de Agosto de 2010, otorgado en Barranquilla inscrito en esta Cámara de Comercio, el 24 de Agosto de 2010 bajo el Nro 4,258 del libro respectivo,-----consta que RUBEN MINSKI GONTOVNIK, varón, mayor de edad, de ésta vecindad, identificado con la cédula de ciudadanía No.7.463.982, expedida en Barranquilla, en mi condición de Representante legal y/o Presidente de la sociedad PROCAPS S. A., conforme a las -----facultades otorgadas por los Estatutos Sociales, todo lo cual -----demuestro con el certificado de existencia y representación legal expedido por la Cámara de Comercio de Barranquilla, que adjunto a este escrito, me permito manifestarles que confiero poder especial, amplio y suficiente al señor MARIO LÓPEZ LEON, varón, mayor de -----edad, de esta vecindad, identificado con la cédula de ciudadanía No.72.311.558, expedida en Puerto Colombia (Atlántico), para que en nombre y representación de la sociedad, realice los siguientes -----actos: 1. Endosar las Facturas Nacionales e Internacionales de esas compañías hasta por la suma de UN MIL MILLONES DE PESOS -----(\$1.000.000.000.00) Moneda Legal. 2. Suscribir Declaraciones -----Cambiarias, Aduaneras y Tributarias a las que esta obligada la -----sociedad en el giro ordinario de sus negocios, quedando facultado para notificarse, aportar y solicitar pruebas relacionados con las declaraciones Cambiarias. El señor MARIO LÓPEZ LEÓN, queda -----facultado para notificarse, aportar y solicitar pruebas, presentar escritos en caso que resulte necesario en general a realizar todo acto, diligencia o tramite que considere indispensable para el -----cabal cumplimiento del presente mandato.-----

C E R T I F I C A

Que en esta Cámara de Comercio no aparecen inscripciones posteriores de documentos referentes a reforma, disolución, liquidación o nombramientos de representantes legales de la expresada sociedad.

C E R T I F I C A

Que su última Renovación fue el: 31 de Marzo de 2011.

La información sobre embargos de establecimiento se suministra en Certificados de Matrícula, la de contratos sujetos a registro, en Certificados Especiales.

C E R T I F I C A

Que los actos de registro aquí certificados quedan en firme cinco días hábiles despues de la correspondiente inscripción, siempre

***** C O N T I N U A *****


CERTIFICADO DE EXISTENCIA Y REPRESENTACION LEGAL O DE INSCRIPCION DE DOCUMENTOS.

PROCAPS S.A.

NIT: 890.106.527-5.

que, dentro de dicho término, no sean objeto de los recursos de reposición ante esta entidad, y/o de apelación para ante la Superintendencia de Industria y Comercio.

ombajes



ANEXO 1



US 20070208056A1

(19) **United States**(12) **Patent Application Publication** (10) Pub. No.: **US 2007/0208056 A1**
Carter et al. (43) Pub. Date: **Sep. 6, 2007**(54) **PIPERIDINYL DERIVATIVES AS
MODULATORS OF CHEMOKINE
RECEPTOR ACTIVITY**

(22) Filed: Jan. 23, 2007

Related U.S. Application Data(75) Inventors: **Percy H. Carter**, Princeton, NJ
(US); **Cullen L. Cavallaro**,
Robbinsville, NJ (US); **John V.**
Duncia, Newtown, PA (US);
Daniel S. Gardner, Furlong, PA
(US); **John Hynes**, Washington
Crossing, PA (US); **Rui-Qin Liu**,
Belle Mead, NJ (US); **Joseph B.**
Santella, Springfield, PA (US);
Dharmpal S. Dodd, Princeton, NJ
(US)(60) Provisional application No. 60/762,801, filed on Jan.
27, 2006.**Publication Classification**(51) Int. Cl.
A61K 31/454 (2006.01)
A61K 31/445 (2006.01)
C07D 211/22 (2006.01)
C07D 401/02 (2006.01)(52) U.S. Cl. **514/317; 514/326; 546/207; 546/221**

Correspondence Address:

LOUIS J. WILLE
BRISTOL-MYERS SQUIBB COMPANY
PATENT DEPARTMENT, P O BOX 4000
PRINCETON, NJ 08543-4000(57) **ABSTRACT**(73) Assignee: **Bristol-Myers Squibb Company**(21) Appl. No.: **11/625,874**

The present application describes substituted piperidinyl modulators of MIP-1 α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.

prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried.

Tablets

[1347] Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Injectable

[1348] A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized.

Suspension

[1349] An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

[1350] Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of the present invention and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.

[1351] Where two or more of the foregoing second therapeutic agents are administered with the compound of the present invention, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination. Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of the present invention and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such


that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

[1352] These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.

[1353] While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.


What is claimed is:

1. A compound of Formula (I):



or stereoisomers or prodrugs or pharmaceutically acceptable salt forms thereof, wherein:

the dashed line represents an optional double bond;



R_1 is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a} :

R_{1a} at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, ---NH_2 , ---CN , ---NO_2 , ---C(=C)OH , $\text{---C(=O)O(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$, $\text{---O(CF}_2\text{)}_{\text{CF}_3}$, $\text{---O(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$, ---OH , ---SH , $\text{---S(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$, $\text{---S(O)}_3\text{H}$, $\text{---P(O)}_3\text{H}_2$, $\text{---C(=O)NR}_9\text{R}_9$, $\text{---NR}_9\text{R}_9$, $\text{---S(O)}_2\text{NR}_9\text{R}_9$, $\text{---NR}_9\text{S(O)}_2\text{(CF}_2\text{)}_{\text{CF}_3}$, $\text{---C(=O)NR}_9\text{S(O)}_2\text{R}_6$, $\text{---S(O)}_2\text{NR}_9\text{C(=O)OR}_6$, $\text{---S(O)}_2\text{NR}_9\text{C(=O)NR}_9\text{R}_9$, $\text{---C(=O)NR}_9\text{S(O)}_2\text{(CF}_2\text{)}_{\text{CF}_3}$, $\text{---C(=O)(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$, $\text{---NR}_9\text{C(=O)H}$, $\text{---NR}_9\text{C(=O)(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$, $\text{---OC(=O)(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$, $\text{---C(=NR}_{14}\text{)NR}_9\text{R}_9$, $\text{---NHC(=NR}_{14}\text{)NR}_{14}\text{R}_{14}$, $\text{---S(=O)(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$, $\text{---S(O)}_2\text{(CR}_8\text{R}_8\text{)}_{\text{R}_{10}}$.

—NR₉C(=O)OR₈, —NR₉S(O₂)R₈, —S(O)₂NR₉C(O)R₆, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R₁₆;

R_{1b}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_R₁₀, —CH₃, —SH, —S(CR₈R₈)_R₁₀, —S(O)₃H, —P(O)₃H₂, —C(=O)NR₉R₆, —NR₉R₆, —S(O)₂NR₉R₆, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₆, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_R₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_R₁₀, —OC(=O)(CR₈R₈)_R₁₀, —C(=NR₁₄)NR₉R₆, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_R₁₀, —S(O)₂(CR₈R₈)_R₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;

R₂ is alkyl, cycloalkyl, cycloalkylalkyl, or alkenyl, wherein the alkyl may be optionally substituted with —OH;

R₃, at each occurrence, is alkyl; or any two R₃'s attached to the same carbon atom may form a 3- to 6-membered ring;

W is hydrogen, F, —OH, —CN, —NH₂;

R₅ is halo, —CN or —Oalkyl; or

W and one R₅ are taken together with the carbon atoms to which each is attached to form a 3- to 6-membered oxygen containing ring wherein said ring may be optionally substituted with one or more R₅'s;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_R₁₀, —OH, —SH, —S(CR₈R₈)_R₁₀, —S(O)₃H, —P(O)₃H₂, —C(=O)NR₉R₆, —NR₉R₆, —S(O)₂NR₉R₆, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₆, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_R₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_R₁₀, —OC(=O)(CR₈R₈)_R₁₀, —C(=NR₁₄)NR₉R₆, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_R₁₀, —S(O)₂(CR₈R₈)_R₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl;

wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₄, —O(CF₂)_rCF₃, —O(CR₈R₈)_R₁₄, —OH, —SH, —S(CR₈R₈)_R₁₄, —S(O)₃H, —P(O)₃H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)_rCF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_R₁₄, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_R₁₄, —OC(=O)(CR₈R₈)_R₁₄, —C(=NR₁₄)NR₁₄R₁₄, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_R₁₄, —S(O)₂(CR₈R₈)_R₁₄, —NR₁₄C(=O)OR₈, —NR₁₄S(O₂)R₈, aryloxy or arylalkyl;


R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m, at each occurrence, is 0-2;


n is 1-3; and

r is 0-5.

2. The compound of claim 1, wherein the compound is a compound of formula (1a):



3. The compound of claim 2, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a};

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_R₁₀, —OH, —SH, —S(CR₈R₈)_R₁₀, —S(O)₃H, —P(O)₃H₂, —C(=O)NR₉R₆, —NR₉R₆, —S(O)₂NR₉R₆, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₆, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_R₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_R₁₀, —OC(=O)(CR₈R₈)_R₁₀,

R₂, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈), R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₈), R₁₀, —OH, —SH, —S(CR₈R₈), R₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)₂CF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₈), R₁₀, —NR₉C(=O)H,

—NR₉C(=O)(CR₈R₈)_nR₁₀, —OC(=O)(CR₈R₈)_nR₁₀,
—C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄,
—S(=O)(CR₈R₈)_nR₁₀, —S(O)₂(CR₈R₈)_nR₁₀,
—NR₉C(=O)OR₈, —NR₉S(O)₂R₈, aryloxy or arylalkyl;

R₂ is alkyl, cycloalkyl, or cycloalkylalkyl, wherein the alkyl may be optionally substituted with —OH;

R₃, at each occurrence, is alkyl; or any two R₃'s attached to the same carbon atom may form a 3- to 6-membered ring;

W is hydrogen, F, —OH, —NH₂;

R₅ is halo or —CN;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_nR₁₀, —O(CF₂)_nCF₃, —O(CR₈R₈)_nR₁₀, —OH, —SH, —S(CR₈R₈)_nR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)_nCF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_nCF₃, —C(=O)(CR₈R₈)_nR₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_nR₁₀, —OC(=O)(CR₈R₈)_nR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_nR₁₀, —S(O)₂(CR₈R₈)_nR₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, aryloxy or arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_nR₁₀, —O(CF₂)_nCF₃, —O(CR₈R₈)_nR₁₀, —OH, —SH, —S(CR₈R₈)_nR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)_nCF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_nCF₃, —C(=O)(CR₈R₈)_nR₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_nR₁₀, —OC(=O)(CR₈R₈)_nR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_nR₁₀, —S(O)₂(CR₈R₈)_nR₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, aryloxy or arylalkyl;


R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m, at each occurrence, is 0-2;

n is 1-2; and

r is 0-3.

5. The compound of claim 2, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a};

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_nR₁₀, —O(CF₂)_nCF₃, —O(CR₈R₈)_nR₁₀, —OH, —SH, —S(CR₈R₈)_nR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_nCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_nCF₃, —C(=O)(CR₈R₈)_nR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_nR₁₀, —OC(=O)(CR₈R₈)_nR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_nR₁₀, —S(O)₂(CR₈R₈)_nR₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1b};

R_{1b}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_nR₁₀, —O(CF₂)_nCF₃, —O(CR₈R₈)_nR₁₀, —OH, —SH, —S(CR₈R₈)_nR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_nCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_nCF₃, —C(=O)(CR₈R₈)_nR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_nR₁₀, —OC(=O)(CR₈R₈)_nR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_nR₁₀, —S(O)₂(CR₈R₈)_nR₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, aryloxy or arylalkyl;

R₂ is alkyl or cycloalkyl, wherein the alkyl may be optionally substituted with —OH;

R₃, at each occurrence, is alkyl; or any two R₃'s attached to the same carbon atom may form a 3- to 6-membered ring;

W is hydrogen, F, —OH, —NH₂;

R₅ is halo;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_{R₁₄}, —O(CF₂)_{R₁₄}, —CF₃, —O(CR₈R₈)_{R₁₄}, —OH, —SH, —S(CR₈R₈)_{R₁₄}, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)_{R₁₄}, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₅, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_{R₁₄}, —CF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₅, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_{R₁₄}, —CF₃, —C(=O)(CR₈R₈)_{R₁₄}, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_{R₁₄}, —OC(=O)(CR₈R₈)_{R₁₄}, —C(=NR₁₄)NR₁₄R₁₄, —NHC

(=NR₁₀)NR₁₄R₁₆, —S(=O)₂(CR₈R₉)₂R₁₀, —S(O)₂(CR₈R₉)₂R₁₄, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl, or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉)₂R₁₀, —O(CF₃)₂, —O(CF₃R₉)₂R₁₀, —CH₃, —SH, —S(CR₈R₉)₂R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₆, —NR₁₄R₁₆, —S(O)₂NR₁₄R₁₆, —NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄S(O)₂R₁₆, —S(O)₂NR₁₄C(=O)OR₈, —S(O)₂NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄C(=O)H, —NR₁₄C(=O)O(CR₈R₉)₂R₁₀, —OC(=O)(CR₈R₉)₂R₁₀, —C(=O)NR₁₄R₁₆, —NHC(=NR₁₄)NR₁₄R₁₆, —S(=O)₂(CR₈R₉)₂R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;


R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m, at each occurrence, is 0-2;

n is 1-2; and

r is 0-2.

7. The compound of claim 2, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, and which may be optionally substituted with 0-5 R_{1a}.

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉)₂R₁₀, —O(CF₃)₂, —O(CR₈R₉)₂R₁₀, —CH₃, —SH, —S(CR₈R₉)₂R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₆, —NR₁₄R₁₆, —S(O)₂NR₁₄R₁₆, —NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄S(O)₂R₁₆, —S(O)₂NR₁₄C(=O)OR₈, —S(O)₂NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄C(=O)H, —NR₁₄C(=O)O(CR₈R₉)₂R₁₀, —OC(=O)(CR₈R₉)₂R₁₀, —C(=O)NR₁₄R₁₆, —NHC(=NR₁₄)NR₁₄R₁₆, —S(=O)₂(CR₈R₉)₂R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1aa}.

R_{1aa}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉)₂R₁₀, —O(CF₃)₂, —O(CR₈R₉)₂R₁₀, —CH₃, —SH, —S(CR₈R₉)₂R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₆, —NR₁₄R₁₆, —S(O)₂NR₁₄R₁₆, —NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄S(O)₂R₁₆, —S(O)₂NR₁₄C(=O)OR₈, —S(O)₂NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄C(=O)H, —NR₁₄C(=O)O(CR₈R₉)₂R₁₀, —OC(=O)(CR₈R₉)₂R₁₀, —C(=O)NR₁₄R₁₆, —NHC(=NR₁₄)NR₁₄R₁₆, —S(=O)₂(CR₈R₉)₂R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

R₁₀, —S(C)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₆, —NR₁₄R₁₆, —S(C)₂R₈R₉, —NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄S(O)₂R₈, —S(O)₂NR₁₄C(=O)OR₈, —S(C)₂NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄C(=O)H, —NR₁₄C(=O)O(CR₈R₉)₂R₁₀, —OC(=O)(CR₈R₉)₂R₁₀, —C(=O)NR₁₄R₁₆, —NHC(=NR₁₄)NR₁₄R₁₆, —S(=O)₂(CR₈R₉)₂R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

R_{1a} is alkyl or cycloalkyl;

R₁, at each occurrence, is alkyl;

m is hydrogen or —OH;

R₂ is H or

R₂, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₁, at each occurrence, is independently hydrogen or alkyl;


R₁, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{1a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉)₂R₁₀, —O(CF₃)₂, —O(CR₈R₉)₂R₁₀, —CH₃, —SH, —S(CR₈R₉)₂R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₆, —NR₁₄R₁₆, —S(O)₂NR₁₄R₁₆, —NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄S(O)₂R₁₆, —S(O)₂NR₁₄C(=O)OR₈, —S(O)₂NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄C(=O)H, —NR₁₄C(=O)O(CR₈R₉)₂R₁₀, —OC(=O)(CR₈R₉)₂R₁₀, —C(=O)NR₁₄R₁₆, —NHC(=NR₁₄)NR₁₄R₁₆, —S(=O)₂(CR₈R₉)₂R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;


R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉)₂R₁₀, —O(CF₃)₂, —O(CR₈R₉)₂R₁₀, —CH₃, —SH, —S(CR₈R₉)₂R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₆, —NR₁₄R₁₆, —S(O)₂NR₁₄R₁₆, —NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄S(O)₂R₁₆, —S(O)₂NR₁₄C(=O)OR₈, —S(O)₂NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄C(=O)NR₁₄R₁₆, —C(=O)NR₁₄C(=O)H, —NR₁₄C(=O)O(CR₈R₉)₂R₁₀, —OC(=O)(CR₈R₉)₂R₁₀, —C(=O)NR₁₄R₁₆, —NHC(=NR₁₄)NR₁₄R₁₆, —S(=O)₂(CR₈R₉)₂R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O₂)R₈, aryloxy or arylalkyl;
 R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
 m, at each occurrence, is 0-2;
 n is 1-2; and
 r is 0-2.
 8. A compound of Formula (Ib):



or stereoisomers or prodrugs or pharmaceutically acceptable salt forms thereof, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a};
 R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, —S(O)₂NR₉C(=O)R₆, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, arylalkyl and arylalkyl may be optionally substituted with 0-3 R_{1a};
 R_{1b}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, —S(O)₂NR₉C(=O)R₆, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, arylalkyl and arylalkyl may be optionally substituted with 0-3 R_{1a};

CF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;

R₂ is alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, —CH₂CH₂CH₂NHC(=NR₁₄)NR₁₄R₁₄, —CH₂CH₂S(CR₈R₈)_rR₁₀ or —CH₂CH₂CN, wherein the alkyl and arylalkyl may be optionally substituted with —OH;

R₄, at each occurrence, is F, —OH or alkyl; or any two alkyl R₄'s attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

W is hydrogen, F, —OH, —CN, —NH₂;

R₅ is halo, —CN or —Oalkyl;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;


R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a} and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;


(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)₂R₁₄, —S(O)₂(CR₈R₈)₂R₁₄, —NR₁₄C(=O)OR₈, —NR₁₄S(O₂)R₈, aryloxy or arylalkyl;
R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;
m, at each occurrence, is 0-2; and
r is 0-5.

9. The compound of claim 8, wherein the compound is a compound of formula (Ib'):



in which W is hydrogen or OH and m is 1 or 2.


10. The compound of claim 9, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a};
R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)₂R₁₀, —C(CF₃)₂, —O(CR₈R₈)₂R₁₀, —OH, —SH, —S(CR₈R₈)₂R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₃)₂, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₃)₂, —CF₃, —C(=O)(CR₈R₈)₂R₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)₂R₁₀, —OC(=O)(CR₈R₈)₂R₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)₂R₁₀, —S(O)₂(CR₈R₈)₂R₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, —S(O)₂NR₉C(O)R₈, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1a};

R_{1b}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)₂R₁₀, —O(CF₃)₂, —O(CR₈R₈)₂R₁₀, —OH, —SH, —S(CR₈R₈)₂R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₃)₂, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₃)₂, —CF₃, —C(=O)(CR₈R₈)₂R₁₀, —NR₉C(=O)H,

—NR₉C(=O)(CR₈R₈)₂R₁₀, —OC(=O)(CR₈R₈)₂R₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)₂R₁₀, —S(O)₂(CR₈R₈)₂R₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;
R₂ is alkyl, cycloalkyl, cycloalkylalkyl, —CH₂CH₂CH₂—NHC(=NH)NH₂, —CH₂CH₂SCH₃, —CH₂CH₂CN



wherein the alkyl may be optionally substituted with —OH;
R₂, at each occurrence, is —OH or alkyl; or any two alkyl R₂'s attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

R₅ is halo, —CN or —Oalkyl;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R₁₀, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)₂R₁₄, —O(CF₃)₂, —O(CR₈R₈)₂R₁₄, —OH, —SH, —S(CR₈R₈)₂R₁₄, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₃)₂, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₃)₂, —CF₃, —C(=O)(CR₈R₈)₂R₁₄, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)₂R₁₄, —OC(=O)(CR₈R₈)₂R₁₄, —C(=NR₁₄)NR₁₄R₁₄, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)₂R₁₄, —S(O)₂(CR₈R₈)₂R₁₄, —NR₁₄C(=O)OR₈, —NR₁₄S(O₂)R₈, aryloxy or arylalkyl;


R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R₁₂, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)₂R₁₄, —O(CF₃)₂, —O(CR₈R₈)₂R₁₄, —OH, —SH, —S(CR₈R₈)₂R₁₄, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₃)₂, —CF₃, —C(=O)(CR₈R₈)₂R₁₄, —NR₁₄C(=O)H,

OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₄, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_rR₁₄, —OC(=O)(CR₈R₈)_rR₁₄, —C(=NR₁₄)NR₁₄R₁₄, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₄, —S(O)₂(CR₈R₈)_rR₁₄, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl; and
r is 0-4.


11. The compound of claim 9, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a};
R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, —S(O)₂NR₉C(O)R₆, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1b};

R_{1b}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)_rCF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, aryloxy or arylalkyl;

R₂ is alkyl, cycloalkyl, cycloalkylalkyl, —CH₂CH₂SCH₃, —CH₂CH₂CN,



wherein the alkyl may be optionally substituted with —OH;

R₄, at each occurrence, is —OH or alkyl; or any two alkyl R₄'s attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

R₅ is halo or —CN;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₄, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₄, —OH, —SH, —S(CR₈R₈)_rR₁₄, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)_rCF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₄, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_rR₁₄, —OC(=O)(CR₈R₈)_rR₁₄, —C(=NR₁₄)NR₁₄R₁₄, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₄, —S(O)₂(CR₈R₈)_rR₁₄, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;


R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₄, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₄, —OH, —SH, —S(CR₈R₈)_rR₁₄, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)_rCF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₄, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_rR₁₄, —OC(=O)(CR₈R₈)_rR₁₄, —C(=NR₁₄)NR₁₄R₁₄, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₄, —S(O)₂(CR₈R₈)_rR₁₄, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl; and

r is 0-3.

12. The compound of claim 9, wherein:




R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a};

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₈)_R₁₀, —OH, —SH, —S(CR₈R₈)_R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)₂CF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₈)_R₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_R₁₀, —OC(=O)(CR₈R₈)_R₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_R₁₀, —S(C)₂(CR₈R₈)_R₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, —S(O)₂NR₉C(=O)R₆, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1b};

R_{1b}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₈)_R₁₀, —OH, —SH, —S(CR₈R₈)_R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₂)₂CF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₈)_R₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_R₁₀, —OC(=O)(CR₈R₈)_R₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_R₁₀, —S(C)₂(CR₈R₈)_R₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₈, aryloxy or arylalkyl;

R₂ is alkyl, cycloalkyl, cycloalkylalkyl,



wherein the alkyl may be optionally substituted with —OH;

R₄, at each occurrence, is alkyl; or any two alkyl R₄'s attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

R₅ is halo;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;


R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₈)_R₁₀, —OH, —SH, —S(CR₈R₈)_R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₈)_R₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_R₁₀, —OC(=O)(CR₈R₈)_R₁₀, —C(=NR₁₄)NR₁₄R₁₄, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_R₁₀, —S(C)₂(CR₈R₈)_R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₈)_R₁₀, —OH, —SH, —S(CR₈R₈)_R₁₀, —S(O)₂H, —P(O)₂H₂, —C(=O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)NR₁₄S(O)₂R₆, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₄, —C(=O)NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₈)_R₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₈)_R₁₀, —OC(=O)(CR₈R₈)_R₁₀, —C(=NR₁₄)NR₁₄R₁₄, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_R₁₀, —S(C)₂(CR₈R₈)_R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O)₂R₈, aryloxy or arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl; and
R is 0-2.

13. The compound of claim 9, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a};

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₈)_R₁₀, —OH, —SH, —S(CR₈R₈)_R₁₀,

R_{10} , $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$,
 $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_3)_r\text{CF}_3$,
 $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_6$,
 $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_r\text{CF}_3$,
 $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_r\text{R}_{10}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$,
 $-\text{NR}_9\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_r\text{R}_{10}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_r\text{R}_{10}$,
 $-\text{C}(=\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$,
 $-\text{S}(=\text{O})(\text{O})\text{CR}_8\text{R}_8\text{R}_{10}$, $-\text{S}(\text{O})_2\text{NR}_9\text{CR}_8\text{R}_{10}$,
 $-\text{NR}_9\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_9\text{S}(\text{O})_2\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(\text{O})\text{R}_6$,
 aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyc-
 clyl heterocyclylalkyl, aryloxy and arylalkyl may be
 optionally substituted with 0-3 R_{16} ;

$R_{1,b}$, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{O}(\text{CF}_2)_n\text{CF}_3$, $-\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_n\text{CF}_3$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_n\text{CF}_3$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$, $-\text{NR}_9\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_9\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R₂ is alkyl, cycloalkyl, or cycloalkylalkyl, wherein the alkyl may be optionally substituted with —OH;

R_4 , at each occurrence, is alkyl;

R_5 is halo;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycli heterocyclialkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{O}(\text{CF}_2)_{R_{14}}$, $-\text{O}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{S}(\text{O})_2\text{H}$, $-\text{P}(\text{O})_2\text{H}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{R}_{14}$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{14}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{14}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14}\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{NHC}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{OR}_6$, $-\text{NR}_{14}\text{S}(\text{O})_2\text{R}_6$, aryloxy or arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl.

wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a} , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

$R_{1,0,2}$, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{O}(\text{CF}_2)_2\text{CF}_3$, $-\text{O}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{1,4}R_{1,4}$, $-\text{NR}_{1,4}R_{1,4}$, $-\text{S}(\text{O})_2\text{NR}_{1,4}R_{1,4}$, $-\text{NR}_{1,4}\text{S}(\text{O})_2(\text{CF}_2)_2\text{CF}_3$, $-\text{C}(=\text{O})\text{NR}_{1,4}\text{S}(\text{O})_2R_{1,4}$, $-\text{S}(\text{O})_2\text{NR}_{1,4}\text{C}(=\text{O})\text{OR}_8$, $-\text{S}(\text{O})_2\text{NR}_{1,4}\text{C}(=\text{O})\text{NR}_{1,4}R_{1,4}$, $-\text{C}(=\text{O})\text{NR}_{1,4}\text{S}(\text{O})_2(\text{CF}_2)_2\text{CF}_3$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{NR}_{1,4}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{1,4}\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{OC}(=\text{O})\text{C}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{C}(=\text{NR}_{1,4})\text{NR}_{1,4}R_{1,4}$, $-\text{NHC}(=\text{NR}_{1,4})\text{NR}_{1,4}R_{1,4}$, $-\text{S}(=\text{O})\text{C}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{S}(\text{O})_2\text{C}(\text{C}_8\text{R}_8)_{R_{1,4}}$, $-\text{NR}_{1,4}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{1,4}\text{S}(\text{O})_2\text{R}_8$, arylloxy or arylalkyl;

R_{14} , at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl; and r is 0-2.

14. The compound of claim 9, wherein:



R₁ is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1c}:

R_{1a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{O}(\text{CF}_2)_{\text{CF}_3}$, $-\text{O}(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_3\text{CF}_3$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_3\text{CF}_3$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$, $-\text{NR}_9\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{OC}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})_2(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2(\text{C}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_9\text{S}(\text{O})_2\text{R}_8$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(\text{O})\text{R}_5$, aryl, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1b} ;

R_{10} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_9)_{\text{R}_{10}}$, $-\text{O}(\text{CF}_2)_n\text{CF}_3$, $-\text{O}(\text{CR}_8\text{R}_9)_{\text{R}_{10}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_9)_{\text{R}_{10}}$, $-\text{S}(\text{O})_n\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_n\text{CF}_3$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_n\text{CF}_3$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_9)_{\text{R}_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$, $-\text{NR}_9\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_9)_{\text{R}_{10}}$, $-\text{OC}(=\text{O})\text{O}(\text{CR}_8\text{R}_9)_{\text{R}_{10}}$, $-\text{C}(\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$,

—S(=O)(CR₈R₉),R₁₀, —S(O)₂(CR₈R₉),R₁₀,
—NR₅C(=O)OR₈, —NR₅S(O₂)R₈, aryloxy or arylalkyl;

R₂ is alkyl or cycloalkyl;

R₄, at each occurrence, is alkyl;

R₅ is halo;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉),R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₉),R₁₀, —OH, —SH, —S(CR₈R₉),R₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₅, —NR₁₄R₁₅, —S(O)₂NR₁₄R₁₅, —NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)NR₁₄S(O)₂R₁₅, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₅, —C(=O)NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₉),R₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₉),R₁₀, —OC(=O)(CR₈R₉),R₁₀, —C(=NR₁₄)NR₁₄R₁₅, —NHC(=NR₁₄)NR₁₄R₁₅, —S(=O)(CR₈R₉),R₁₀, —S(O)₂(CR₈R₉),R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O₂)R₈, aryloxy or arylalkyl;


R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, C, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉),R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₉),R₁₀, —OH, —SH, —S(CR₈R₉),R₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₅, —NR₁₄R₁₅, —S(O)₂NR₁₄R₁₅, —NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)NR₁₄S(O)₂R₁₅, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₅, —C(=O)NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₉),R₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₉),R₁₀, —OC(=O)(CR₈R₉),R₁₀, —C(=NR₁₄)NR₁₄R₁₅, —NHC(=NR₁₄)NR₁₄R₁₅, —S(=O)(CR₈R₉),R₁₀, —S(O)₂(CR₈R₉),R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O₂)R₈, aryloxy or arylalkyl;


R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl; and
r is 0-2.

15. The compound of claim 9, wherein R₂ is isopropyl, sec-butyl or cyclopropyl; R₄ is methyl; R₅ is Cl, F or Br; and R₁ is alkyl, cycloalkyl, aryl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a}.

16. The compound of claim 15, wherein:



17. A compound of formula (1c):



or stereoisomers or prodrugs or pharmaceutically acceptable salt forms thereof, wherein:

R₁₅ is —NHR₁, heteroaryl or aryl, wherein the heteroaryl and aryl may be optionally substituted with 0-3 R_{1a};

R₁ is aryl or heteroaryl, both of which may be optionally substituted with 0-3 R_{1a}, provided that when R₁ is phenyl, R_{1a} cannot be ortho-methoxy;

R₂, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉),R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₉),R₁₀, —OH, —SH, —S(CR₈R₉),R₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₅, —NR₁₄R₁₅, —S(O)₂NR₁₄R₁₅, —NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)NR₁₄S(O)₂R₁₅, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₅, —C(=O)NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₉),R₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₉),R₁₀, —OC(=O)(CR₈R₉),R₁₀, —C(=NR₁₄)NR₁₄R₁₅, —NHC(=NR₁₄)NR₁₄R₁₅, —S(=O)(CR₈R₉),R₁₀, —S(O)₂(CR₈R₉),R₁₀, —NR₁₄C(=O)OR₈, —NR₁₄S(O₂)R₈, —S(O)₂NR₁₄C(=O)OR₈, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, aryloxy or arylalkyl may be optionally substituted with 0-3 R_{1a};

R₁₆, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₉),R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₉),R₁₀, —OH, —SH, —S(CR₈R₉),R₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₁₄R₁₅, —NR₁₄R₁₅, —S(O)₂NR₁₄R₁₅, —NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)NR₁₄S(O)₂R₁₅, —S(O)₂NR₁₄C(=O)OR₆, —S(O)₂NR₁₄C(=O)NR₁₄R₁₅, —C(=O)NR₁₄S(O)₂(CF₂)₂CF₃, —C(=O)(CR₈R₉),R₁₀, —NR₁₄C(=O)H, —NR₁₄C(=O)(CR₈R₉),R₁₀, —OC(=O)(CR₈R₉),R₁₀, —C(=NR₁₄)NR₁₄R₁₅, —NHC(=NR₁₄)NR₁₄R₁₅,

—S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀,
—NR₅C(=O)OR₆, —NR₅S(O₂)R₈, aryloxy or arylalkyl;

R₂ is alkyl, cycloalkyl or cycloalkylalkyl, wherein the alkyl may be optionally substituted with —OH;

R₄, at each occurrence, is F, —OH or alkyl; or any two alkyl R₄'s attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

W is hydrogen, F, —OH or —NH₂;

R₅ is halo, —CN or —Oalkyl;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the [k' aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O₂)(CF₂)_rCF₃, —C(=O)NR₉S(O₂)R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O₂)(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, —S(O)₂NR₉C(=O)OR₆, aryloxy or arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O₂)(CF₂)_rCF₃, —C(=O)NR₉S(O₂)R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O₂)(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;


R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m, at each occurrence, is 0-2;

n is 1-3; and

r is 0-5.

18. The compound of claim 17, wherein the compound is a compound of formula (Id):



19. The compound of claim 17, wherein:

R₁₅ is —NHR₁, heteroaryl or aryl, wherein the heteroaryl and aryl may be optionally substituted with 0-3 R_{1a};

R₁ is aryl or heteroaryl, both of which may be optionally substituted with 0-3 R_{1a};

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O₂)(CF₂)_rCF₃, —C(=O)NR₉S(O₂)R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O₂)(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, —S(O)₂NR₉C(=O)OR₆, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1b};

R_{1b}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈)_rR₁₀, —O(CF₂)_rCF₃, —O(CR₈R₈)_rR₁₀, —OH, —SH, —S(CR₈R₈)_rR₁₀, —S(O)₂H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O₂)(CF₂)_rCF₃, —C(=O)NR₉S(O₂)R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)NR₉R₉, —C(=O)NR₉S(O₂)(CF₂)_rCF₃, —C(=O)(CR₈R₈)_rR₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈)_rR₁₀, —OC(=O)(CR₈R₈)_rR₁₀, —C(=NR₁₄)NR₉R₉, —NHC(=NR₁₄)NR₁₄R₁₄, —S(=O)(CR₈R₈)_rR₁₀, —S(O)₂(CR₈R₈)_rR₁₀, —NR₉C(=O)OR₈, —NR₉S(O₂)R₈, aryloxy or arylalkyl;

R₂ is alkyl or cycloalkyl, wherein the alkyl may be optionally substituted with —OH;

R₄, at each occurrence, is F, —OH or alkyl; or any two alkyl R₄'s attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

W is hydrogen, F, or —OH;

R₅ is halo, —CN or —Oalkyl;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{C}(\text{R}_8\text{R}_8)_{R_{14a}})-\text{O}(\text{CF}_2)_r\text{CF}_3$, $-\text{O}(\text{C}(\text{R}_8\text{R}_8)_{R_{14a}})-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{C}(\text{R}_8\text{R}_8)_{R_{14a}})\text{S}(\text{O})_2\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{14R_{14a}}$, $-\text{NR}_{14R_{14a}}$, $-\text{S}(\text{O})_2\text{NR}_{14R_{14a}}$, $-\text{NR}_{14R_{14a}}\text{S}(\text{O})_2(\text{CF}_2)_r\text{CF}_3$, $-\text{C}(=\text{O})\text{NR}_{14R_{14a}}\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_{14R_{14a}}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14R_{14a}}\text{C}(=\text{O})\text{NR}_{14R_{14a}}$, $-\text{C}(=\text{O})\text{NR}_{14R_{14a}}\text{S}(\text{O})_2(\text{CF}_2)_r\text{CF}_3$, $-\text{C}(=\text{O})\text{C}(\text{R}_8\text{R}_8)_{R_{14a}}-\text{NR}_{14R_{14a}}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14R_{14a}}\text{C}(=\text{O})\text{C}(\text{R}_8\text{R}_8)_{R_{14a}}-\text{OC}(=\text{O})\text{C}(\text{R}_8\text{R}_8)_{R_{14a}}$, $-\text{C}(=\text{NR}_{14R_{14a}})\text{NR}_{14R_{14a}}$, $-\text{NHC}(\text{NR}_{14R_{14a}})\text{NR}_{14R_{14a}}$, $-\text{S}(=\text{O})\text{C}(\text{R}_8\text{R}_8)_{R_{14a}}-\text{S}(\text{O})_2\text{C}(\text{R}_8\text{R}_8)_{R_{14a}}$, $-\text{NR}_{14R_{14a}}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14R_{14a}}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R_{10a}, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

$R_{1,0a}$, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{O}(\text{CF}_2)_n\text{CF}_3$, $-\text{O}(\text{CR}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{1,4}\text{R}_{1,4}$, $-\text{NR}_{1,4}\text{R}_{1,4}$, $-\text{S}(\text{O})_2\text{NR}_{1,4}\text{R}_{1,4}$, $-\text{NR}_{1,4}\text{S}(\text{O})_2(\text{CF}_2)_n\text{CF}_3$, $-\text{C}(=\text{O})\text{NR}_{1,4}\text{S}(\text{O})_2\text{R}_8$, $-\text{S}(\text{O})_2\text{NR}_{1,4}\text{C}(=\text{O})\text{OR}_8$, $-\text{S}(\text{O})_2\text{NR}_{1,4}\text{C}(=\text{O})\text{NR}_{1,4}\text{R}_{1,4}$, $-\text{C}(=\text{O})\text{NR}_{1,4}\text{S}(\text{O})_2(\text{CF}_2)_n\text{CF}_3$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{NR}_{1,4}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{1,4}\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{OC}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{C}(=\text{NR}_{1,4})\text{NR}_{1,4}\text{R}_{1,4}$, $-\text{NHC}(=\text{NR}_{1,4})\text{NR}_{1,4}\text{R}_{1,4}$, $-\text{S}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{S}(\text{O})_2\text{O}(\text{CR}_8\text{R}_8)$, $\text{R}_{1,4}$, $-\text{NR}_{1,4}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{1,4}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m, at each occurrence, is 0-2;

n is 1-2; and

r is 0-4.

20. The compound of claim 17, wherein:

R₁₅ is —NHR₁, heteroaryl or aryl, wherein the heteroaryl and aryl may be optionally substituted with 0-3 R₁₆;

R₁ is aryl or heteroaryl, which may be optionally substituted with 0-3 R_{1a};

$R_{1,2}$, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocy-

cyl) heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{O}(\text{CF}_2)_2\text{CF}_3$, $-\text{O}(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_2\text{CF}_3$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_2\text{CF}_3$, $-\text{C}(=\text{O})(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$, $-\text{NR}_9\text{C}(=\text{O})(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{OC}(=\text{O})(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{C}(=\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{S}(\text{O})(\text{C}_8\text{R}_8)_3\text{R}_{10}$, $-\text{NR}_9\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_9\text{S}(\text{O})_2\text{R}_8$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(\text{O})\text{R}_6$, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1k} ;

R_{1,5}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(=O)OH, —C(=O)O(CR₈R₈), R₁₀, —O(CF₂)₂CF₃, —O(CR₈R₈), R₁₀, —OH, —SH, —S(CR₈R₈), R₁₀, —S(O)₃H, —P(O)₃H₂, —C(=O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂(CF₃)₂CF₃, —C(=O)NR₉S(O)₂R₆, —S(O)₂NR₉C(=O)OR₆, —S(O)₂NR₉C(=O)OR₉, —C(=O)NR₉S(O)₂(CF₃)₂CF₃, —C(=O)(CR₈R₈), R₁₀, —NR₉C(=O)H, —NR₉C(=O)(CR₈R₈), R₁₀, —OC(=O)(CR₈R₈), R₁₀, —C(=NR₁₂)NR₉R₉, —NHCC(=NR₁₄)NR₁₂R₁₂, —S(=O)(CR₈R₈), R₁₀, —S(O)₂(CR₈R₈), R₁₀, —NR₉C(=O)OR₈, —NR₉S(O)₂R₉, aryloxy or arylalkyl;

R₂ is alkyl or cycloalkyl, wherein the alkyl may be optionally substituted with —OH;

R₄'s, at each occurrence, is OH or alkyl; or any two alkyl R₄'s attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

W is hydrogen or $-\text{OH}$;

R_2 is halo or $-\text{CN}$:

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R_g, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycl or heterocyclalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycl or heterocyclalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocycl or heterocyclalkyl contain 1-4 heteroatoms selected from N, O, and S;

$R_{9,2}$, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycyl heterocyclylalkyl, halo, $-NH_2$, $-CN$, $-NO_2$, $-C(=O)OH$, $-C(=O)O(CR_8R_8)_{R_{1,4}}$, $-O(CF_2)_nCF_3$, $-O(CR_8R_8)_{R_{1,4}}$, $-OH$, $-SH$, $-S(CR_8R_8)_{R_{1,4}}$, $-S(O)_2H$, $-P(O)_2H$, $-C(=O)NR_{1,4}R_{1,6}$, $-NR_{1,4}R_{1,4}$, $-S(O)_2NR_{1,4}R_{1,4}$, $-NR_{1,4}S(O)_2(CF_2)_nCF_3$, $-C(=O)NR_{1,4}S(O)_2R_6$, $-S(O)_2NR_{1,4}C(=O)OR_6$, $-S(O)_2NR_{1,4}C(=O)NR_{1,4}R_{1,4}$, $-C(=O)NR_{1,4}S(O)_2(CF_2)_nCF_3$, $-C(=O)(CR_8R_8)_{R_{1,4}}$, $-NR_{1,4}C$

$$\begin{array}{l} \text{(=O)}_2\text{H}, \quad \text{---NR}_{14}\text{C(=O)(CR}_8\text{R}_8)_8\text{R}_{14}, \quad \text{---OC(=O)} \\ \text{(CR}_8\text{R}_8)_8\text{R}_{14}, \quad \text{---C(=NR}_{14}\text{)NR}_{14}\text{R}_{14}, \quad \text{---NHC} \\ \text{(=NR}_{14}\text{)NR}_{14}\text{R}_{14}, \quad \text{---S(=O)(CR}_8\text{R}_8)_8\text{R}_{14}, \quad \text{---S(O)}_2 \\ \text{(CR}_8\text{R}_8)_8\text{R}_{14}, \quad \text{---NR}_{14}\text{C(=O)OR}_8, \quad \text{---NR}_{14}\text{S(O)}_2\text{R}_8, \\ \text{aryloxy or arylalkyl:} \end{array}$$

R₁₀, at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

$R_{1,0a}$, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_9)_{R_{14}}$, $-\text{O}(\text{CF}_2)_{R_{14}}$, $-\text{O}(\text{CR}_8\text{R}_9)_{R_{14}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_9)_{R_{14}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{14R_{14}}$, $-\text{NR}_{14R_{14}}$, $-\text{S}(\text{O})_2\text{NR}_{14R_{14}}$, $-\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{14}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2R_{14}$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{NR}_{14R_{14}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{14}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{C}(=\text{O})\text{NR}_{14R_{14}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14}\text{C}(=\text{O})(\text{CR}_8\text{R}_9)_{R_{14}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_9)_{R_{14}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_{14R_{14}}$, $-\text{NHC}(\text{NR}_{14})\text{NR}_{14R_{14}}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_9)_{R_{14}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_9)_{R_{14}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R_{14} , at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl:

m, at each occurrence, is 0-2;

n is 1-2; and

r is 0-3.

21. The compound of claim 17, wherein:

R₁₅ is —NHR₁, heteroaryl or aryl, wherein the heteroaryl and aryl may be optionally substituted with 0-3 R₁;

R₁ is aryl or heteroaryl, which may be optionally substituted with 0-3 R_{1c};

R_{1a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, -NH₂, -CN, -NO₂, -C(=O)OH, -C(=O)O(CR₈R₈), R₁₀, -O(CF₂)_nCF₃, -O(CR₈R₈), R₁₀, -OH, -SH, -S(CR₈R₈), R₁₀, -S(C)₃H₇, -P(O)₃H₂, -C(=O)NR₉R₉, -NR₉R₉, -S(O)₂NR₉R₉, -NR₉S(O)₂(CF₂)_nCF₃, -C(=C)NR₉S(O)₂R₈, -S(O)₂NR₉C(=O)OR₈, -S(O)₂NR₉C(=O)NR₉R₉, -C(=O)NR₉S(O)₂(CF₂)_nCF₃, -C(=O)(CR₈R₈), R₁₀, -NR₉C(=O)H, -NR₉C(=O)(CR₈R₈), R₁₀, -OC(=O)(CR₈R₈), R₁₀, -C(=NR₁₄)NR₉R₉, -NHC(=NR₁₄)NR₉R₁₄, -S(=O)(CR₈R₈), R₁₀, -S(O)₂(CR₈R₈), R₁₀, -NR₉C(=O)OR₈, -NR₉S(O)₂R₈, -S(O)₂NR₉C(O)R₆, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1a}.

R_{10} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{C}_6\text{H}_5)_2$, $-\text{O}(\text{CF}_2)_2$, $-\text{CF}_3$, $-\text{O}(\text{C}_6\text{H}_5)_2$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{C}_6\text{H}_5)_2$, $-\text{R}_{10}$, $-\text{S}(\text{O})_2\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9$, $-\text{NR}_9\text{R}_2$, $-\text{S}(\text{O})_2\text{NR}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_2\text{CF}_3$.

$$\begin{array}{ll} -C(=O)NR_6S(O)_2R_6, & -S(O)_2NR_9C(=O)OR_6, \\ -S(O)_2NR_9C(=O)NR_9R_9, & -C(=O)NR_9S(O)_2(CF_2)_{CF_3}, \\ & -C(=O)(CR_8R_8)R_{10}, \quad -NR_9C(=O)H, \\ -NR_9C(=O)(CR_8R_8)R_{10}, & -OC(=O)(CR_8R_8)R_{10}, \\ -C(=NR_{14})NR_9R_9, & -NHC(=NR_{14})NR_{14}R_{14}, \\ -S(=O)(CR_8R_8)R_{10}, & -S(O)_2(CR_8R_8)R_{10}, \\ -NR_9C(=O)OR_8, & -NR_9S(O)_2R_8, \end{array}$$

alkyl; aryl; aryloxy or arylalkyl;

R_2 is alkyl or cycloalkyl, wherein the alkyl may be optionally substituted with $-\text{OH}$;

R_4 , at each occurrence, is alkyl; or any two R_4 's attached to the same carbon atom may form a 3- to 6-membered ring, which optionally may contain 1-4 heteroatoms selected from N, O, and S;

W is hydrogen or —OH ;

R₅ is halo;

R₆, at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl¹, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R₈, at each occurrence, is independently hydrogen or alkyl;

R₉, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a}, and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a} : at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{1,4}$, $-\text{O}(\text{C}_2\text{F}_2)_{1,4}$, $-\text{O}(\text{C}_8\text{R}_8)_{1,4}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{C}_8\text{R}_8)_{1,4}$, $-\text{S}(\text{O})_2\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{14,1,4}$, $-\text{NR}_{14,1,4}$, $-\text{S}(\text{O})_2\text{NR}_{14,1,4}$, $-\text{NR}_{14,1,4}\text{S}(\text{O})_2(\text{C}_2\text{F}_2)_{1,4}$, $-\text{C}(=\text{O})\text{NR}_{14,1,4}\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_{14,1,4}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14,1,4}\text{C}(=\text{O})\text{NR}_{14,1,4}$, $-\text{C}(=\text{O})\text{NR}_{14,1,4}\text{S}(\text{O})_2(\text{C}_2\text{F}_2)_{1,4}$, $-\text{C}(=\text{O})\text{O}(\text{C}_8\text{R}_8)_{1,4}$, $-\text{NR}_{14,1,4}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14,1,4}\text{C}(=\text{O})(\text{C}_8\text{R}_8)_{1,4}$, $-\text{OC}(=\text{O})(\text{C}_8\text{R}_8)_{1,4}$, $-\text{C}(=\text{NR}_{14,1,4})\text{NR}_{14,1,4}$, $-\text{NHC}(\text{NR}_{14,1,4})\text{NR}_{14,1,4}$, $-\text{S}(=\text{O})(\text{C}_8\text{R}_8)_{1,4}$, $-\text{S}(\text{O})_2(\text{C}_8\text{R}_8)_{1,4}$, $-\text{NR}_{14,1,4}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14,1,4}\text{S}(\text{O}_2)\text{R}_8$, arloxy or arylalkyl;

R_{10a} at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a}, and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{1,0a}, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, -NH₂, -CN, -NO₂, -C(=O)OH, -C(=O)O(CR₈R₈), R_{1,4}, -O(CF₂)₂CF₃, -O(CR₈R₈), R_{1,4}, -OH, -SH, -S(CR₈R₈), R_{1,4}, -S(O)₂H, -P(O)₃H₂, -C(=O)NR_{1,4}R_{1,4}, -NR_{1,4}R_{1,4}, -S(O)₂NR_{1,4}R_{1,4}, -NR_{1,4}S(O)₂(CF₂)₂CF₃, -C(=O)NR_{1,4}S(O)₂R_{1,4}, -S(O)₂NR_{1,4}C(=O)CR₈, -S(O)₂NR_{1,4}C(=O)NR_{1,4}S(O)₂(CF₂)₂CF₃, -C(=O)(CR₈R₈), R_{1,4}, -NR_{1,4}C(=O)H, -NR_{1,4}C(=O)(CR₈R₈), R_{1,4}, -OC(=O)(CR₈R₈), R_{1,4}, -C(=NR_{1,4})NR_{1,4}R_{1,4}, -NHC

$(=NR_{14})NR_{14}R_{14}$, $-S(=O)(CR_8R_8)_{R_{10}}$, $-S(O)_2(CR_8R_8)_{R_{10}}$, $-NR_{14}C(=O)OR_8$, $-NR_{14}S(O_2)R_8$, aryloxy or arylalkyl;

R_{14} , at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m , at each occurrence, is 0-2;

n is 1-2; and

r is 0-2.

22. The compound of claim 17, wherein:

R_{15} is $-NHR_1$ or heteroaryl, wherein the heteroaryl may be optionally substituted with 0-3 R_{1a} ;

R_1 is aryl or heteroaryl, which may be optionally substituted with 0-3 R_{1a} ;

R_{1a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-NH_2$, $-CN$, $-NO_2$, $-C(=O)OH$, $-C(=O)O(CR_8R_8)_{R_{10}}$, $-O(CF_2)_2CF_3$, $-O(CR_8R_8)_{R_{10}}$, $-OH$, $-SH$, $-S(CR_8R_8)_{R_{10}}$, $-S(O)_2H$, $-P(O)_3H_2$, $-C(=O)NR_9R_9$, $-NR_9R_9$, $-S(O)_2NR_9R_9$, $-NR_9S(O)_2(CF_2)_2CF_3$, $-C(=O)NR_9S(O)_2R_6$, $-S(O)_2NR_9C(=O)OR_6$, $-S(O)_2NR_9C(=O)NR_9R_9$, $-C(=O)NR_9S(O)_2(CF_2)_2CF_3$, $-C(=O)(CR_8R_8)_{R_{10}}$, $-NR_9C(=O)H$, $-NR_9C(=O)(CR_8R_8)_{R_{10}}$, $-OC(=O)(CR_8R_8)_{R_{10}}$, $-C(=NR_{14})NR_9R_9$, $-NHC(=NR_{14})NR_{14}R_{14}$, $-S(=O)(CR_8R_8)_{R_{10}}$, $-S(O)_2(CR_8R_8)_{R_{10}}$, $-NR_9C(=O)OR_8$, $-NR_9S(O_2)R_8$, $-S(O)_2NR_9C(O)R_6$, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1a} ;

R_{1b} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-NH_2$, $-CN$, $-NO_2$, $-C(=O)OH$, $-C(=O)O(CR_8R_8)_{R_{10}}$, $-O(CF_2)_2CF_3$, $-O(CR_8R_8)_{R_{10}}$, $-OH$, $-SH$, $-S(CR_8R_8)_{R_{10}}$, $-S(O)_2H$, $-P(O)_3H_2$, $-C(=O)NR_9R_9$, $-NR_9R_9$, $-S(O)_2NR_9R_9$, $-NR_9S(O)_2(CF_2)_2CF_3$, $-C(=O)NR_9S(O)_2R_6$, $-S(O)_2NR_9C(=O)OR_6$, $-S(O)_2NR_9C(=O)NR_9R_9$, $-C(=O)NR_9S(O)_2(CF_2)_2CF_3$, $-C(=O)(CR_8R_8)_{R_{10}}$, $-NR_9C(=O)H$, $-NR_9C(=O)(CR_8R_8)_{R_{10}}$, $-OC(=O)(CR_8R_8)_{R_{10}}$, $-C(=NR_{14})NR_9R_9$, $-NHC(=NR_{14})NR_{14}R_{14}$, $-S(=O)(CR_8R_8)_{R_{10}}$, $-S(O)_2(CR_8R_8)_{R_{10}}$, $-NR_9C(=O)OR_8$, $-NR_9S(O_2)R_8$, aryloxy or arylalkyl;

R_2 is alkyl or cycloalkyl, wherein the alkyl may be optionally substituted with $-OH$;

R_3 , at each occurrence, is alkyl;

W is hydrogen or $-OH$;

R_5 is halo;

R_6 , at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R_8 , at each occurrence, is independently hydrogen or alkyl;

R_9 , at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a} , and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

alkyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-NH_2$, $-CN$, $-NO_2$, $-C(=O)OH$, $-C(=O)O(CR_8R_8)_{R_{10}}$, $-O(CF_2)_2CF_3$, $-O(CR_8R_8)_{R_{10}}$, $-OH$, $-SH$, $-S(CR_8R_8)_{R_{10}}$, $-S(O)_2H$, $-P(O)_3H_2$, $-C(=O)NR_{14}R_{14}$, $-NR_{14}R_{14}$, $-S(O)_2NR_{14}R_{14}$, $-NR_{14}S(O)_2(CF_2)_2CF_3$, $-C(=O)NR_{14}S(O)_2R_6$, $-S(O)_2NR_{14}C(=O)OR_6$, $-S(O)_2NR_{14}C(=O)NR_{14}R_{14}$, $-C(=O)NR_{14}S(O)_2(CF_2)_2CF_3$, $-C(=O)(CR_8R_8)_{R_{10}}$, $-NR_{14}C(=O)H$, $-NR_{14}C(=O)(CR_8R_8)_{R_{10}}$, $-OC(=O)(CR_8R_8)_{R_{10}}$, $-C(=NR_{14})NR_{14}R_{14}$, $-NHC(=NR_{14})NR_{14}R_{14}$, $-S(=O)(CR_8R_8)_{R_{10}}$, $-S(O)_2(CR_8R_8)_{R_{10}}$, $-NR_{14}C(=O)OR_8$, $-NR_{14}S(O_2)R_8$, aryloxy or arylalkyl;

R_{10} , at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a} , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{12} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-NH_2$, $-CN$, $-NO_2$, $-C(=O)OH$, $-C(=O)O(CR_8R_8)_{R_{10}}$, $-O(CF_2)_2CF_3$, $-O(CR_8R_8)_{R_{10}}$, $-OH$, $-SH$, $-S(CR_8R_8)_{R_{10}}$, $-S(O)_2H$, $-P(O)_3H_2$, $-C(=O)NR_{14}R_{14}$, $-NR_{14}R_{14}$, $-S(O)_2NR_{14}R_{14}$, $-NR_{14}S(O)_2(CF_2)_2CF_3$, $-C(=O)NR_{14}S(O)_2R_6$, $-S(O)_2NR_{14}C(=O)OR_6$, $-S(O)_2NR_{14}C(=O)NR_{14}R_{14}$, $-C(=O)NR_{14}S(O)_2(CF_2)_2CF_3$, $-C(=O)(CR_8R_8)_{R_{10}}$, $-NR_{14}C(=O)H$, $-NR_{14}C(=O)(CR_8R_8)_{R_{10}}$, $-OC(=O)(CR_8R_8)_{R_{10}}$, $-C(=NR_{14})NR_{14}R_{14}$, $-NHC(=NR_{14})NR_{14}R_{14}$, $-S(=O)(CR_8R_8)_{R_{10}}$, $-S(O)_2(CR_8R_8)_{R_{10}}$, $-NR_{14}C(=O)OR_8$, $-NR_{14}S(O_2)R_8$, aryloxy or arylalkyl;

R_{14} , at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m , at each occurrence, is 0-2;

n is 1-2; and

r is 0-2.

23. The compound of claim 17, wherein:

R_{15} is $-NHR_1$;

R_1 is aryl or heteroaryl, which may be optionally substituted with 0-3 R_{1a} ;

R_{1a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-NH_2$, $-CN$, $-NO_2$, $-C(=O)OH$, $-C(=O)O(CR_8R_8)_{R_{10}}$, $-O(CF_2)_2CF_3$, $-O(CR_8R_8)_{R_{10}}$, $-OH$, $-SH$, $-S(CR_8R_8)_{R_{10}}$, $-S(O)_2H$, $-P(O)_3H_2$, $-C(=O)NR_9R_9$, $-NR_9R_9$, $-S(O)_2NR_9R_9$, $-NR_9S(O)_2(CF_2)_2CF_3$, $-C(=O)NR_9S(O)_2R_6$, $-S(O)_2NR_9C(=O)OR_6$, $-S(O)_2NR_9C(=O)NR_9R_9$, $-C(=O)NR_9S(O)_2(CF_2)_2CF_3$, $-C(=O)(CR_8R_8)_{R_{10}}$, $-NR_9C(=O)H$, $-NR_9C(=O)(CR_8R_8)_{R_{10}}$, $-OC(=O)(CR_8R_8)_{R_{10}}$, $-C(=NR_{14})NR_9R_9$, $-NHC(=NR_{14})NR_{14}R_{14}$, $-S(=O)(CR_8R_8)_{R_{10}}$, $-S(O)_2(CR_8R_8)_{R_{10}}$, $-NR_9C(=O)OR_8$, $-NR_9S(O_2)R_8$, $-S(O)_2NR_9C(O)R_6$, aryloxy or arylalkyl;

R_6 , aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1b} ;

R_{1b} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{O}(\text{CF}_2)_{R_{10}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$, $-\text{NR}_9\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_9\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R_2 is alkyl or cycloalkyl;

R_3 , at each occurrence, is alkyl;

W is hydrogen or $-\text{OH}$;

R_5 is halo;

R_6 , at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R_8 , at each occurrence, is independently hydrogen or alkyl;

R_9 , at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a} , and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{O}(\text{CF}_2)_{R_{10}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{R}_{14}$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14}\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R_{10} , at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a} , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{O}(\text{CF}_2)_{R_{10}}$,

$-\text{CF}_3$, $-\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{R}_{14}$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14}\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;


R_{14} , at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m, at each occurrence, is 0-2;

n is 1-2; and


r is 0-2.

24. A compound of Formula (Ie):



or stereoisomers or prodrugs or pharmaceutically acceptable salt forms thereof, wherein:

the dashed line represents an optional double bond;



R_1 is alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, all of which may be optionally substituted with 0-5 R_{1a} ;

R_{1a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{O}(\text{CF}_2)_{R_{10}}$, $-\text{S}(\text{O})_3\text{H}$, $-\text{P}(\text{O})_3\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_{R_{10}}$, $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$, $-\text{NR}_9\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_9\text{S}(\text{O})_2\text{R}_8$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{R}_6$, aryloxy or arylalkyl, wherein the aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl heterocyclylalkyl, aryloxy and arylalkyl may be optionally substituted with 0-3 R_{1b} ;

R_{1b} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,

cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{O}(\text{CF}_2)_3$, $-\text{O}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2\text{H}$, $-\text{P}(\text{O})_2\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{R}_9$, $-\text{S}(\text{O})_2\text{NR}_9\text{R}_9$, $-\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_3$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_9\text{C}(=\text{O})\text{NR}_9\text{R}_9$, $-\text{C}(=\text{O})\text{NR}_9\text{S}(\text{O})_2(\text{CF}_2)_3$, $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{H}$, $-\text{NR}_9\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_9\text{R}_9$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{10}}$, $-\text{NR}_9\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_9\text{S}(\text{O})_2\text{R}_9$, aryloxy or arylalkyl;

R_2 is alkyl, cycloalkyl, cycloalkylalkyl, or alkenyl, wherein the alkyl may be optionally substituted with $-\text{OH}$;

R_3 is halo, $-\text{CN}$ or $-\text{Oalkyl}$;

R_5 , at each occurrence, is independently alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R_8 , at each occurrence, is independently hydrogen or alkyl;

R_9 , at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-5 R_{9a} , and the heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{9a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{O}(\text{CF}_2)_3$, $-\text{O}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{S}(\text{O})_2\text{H}$, $-\text{P}(\text{O})_2\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{R}_{14}$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_3$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_3$, $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14}\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R_{10} , at each occurrence, is independently selected from alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the alkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally substituted with 0-3 R_{10a} , and the heterocyclyl and heterocyclylalkyl contain 1-4 heteroatoms selected from N, O, and S;

R_{10a} , at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, $-\text{NH}_2$, $-\text{CN}$, $-\text{NO}_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{O}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{O}(\text{CF}_2)_3$, $-\text{O}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{OH}$, $-\text{SH}$, $-\text{S}(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{S}(\text{O})_2\text{H}$, $-\text{P}(\text{O})_2\text{H}_2$, $-\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{R}_{14}$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{R}_{14}$, $-\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_3$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2\text{R}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{OR}_6$, $-\text{S}(\text{O})_2\text{NR}_{14}\text{C}(=\text{O})\text{NR}_{14}\text{R}_{14}$, $-\text{C}(=\text{O})\text{NR}_{14}\text{S}(\text{O})_2(\text{CF}_2)_3$, $-\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{H}$, $-\text{NR}_{14}\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

$(=\text{O})\text{H}$, $-\text{NR}_{14}\text{C}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{OC}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{C}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{NHC}(=\text{NR}_{14})\text{NR}_{14}\text{R}_{14}$, $-\text{S}(=\text{O})(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{S}(\text{O})_2(\text{CR}_8\text{R}_8)_{R_{14}}$, $-\text{NR}_{14}\text{C}(=\text{O})\text{OR}_8$, $-\text{NR}_{14}\text{S}(\text{O})_2\text{R}_8$, aryloxy or arylalkyl;

R_{14} , at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl or phenyl;

m , at each occurrence, is 0-2;

n is 1-3; and

r is 0-5.

25. A compound selected from the compounds exemplified in the examples.

26. A pharmaceutical composition comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of claim 1.

27. A method for treating a disorder comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of claim 1, wherein said disorder is selected from osteoarthritis, aneurysm, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, arteriosclerosis, rheumatoid arthritis, restinosis, organ transplantation, psoriatic arthritis, multiple myeloma, allergies, hepatocellular carcinoma, osteoporosis, renal fibrosis and cancer.

28. A pharmaceutical composition comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of claim 9.

29. A method for treating a disorder comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of claim 9, wherein said disorder is selected from osteoarthritis, aneurysm, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, arteriosclerosis, rheumatoid arthritis, restinosis, organ transplantation, psoriatic arthritis, multiple myeloma, allergies, hepatocellular carcinoma, osteoporosis, renal fibrosis and cancer.

30. A pharmaceutical composition comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of claim 17.

31. A method for treating a disorder comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of claim 17, wherein said disorder is selected from osteoarthritis, aneurysm, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, arteriosclerosis, rheumatoid arthritis, restinosis, organ trans-

plantation, psoriatic arthritis, multiple myeloma, allergies, hepatocellular carcinoma, osteoporosis, renal fibrosis and cancer.

32. A pharmaceutical composition comprised of a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of claim 24.

33. A method for treating a disorder comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of claim 24, wherein said disorder is selected from osteoarthritis, aneurysm, fever, cardiovascular effects, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associ-

ated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nephritis, glomerulonephritis, asthma, multiple sclerosis, arteriosclerosis, rheumatoid arthritis, retinosis, organ transplantation, psoriatic arthritis, multiple myeloma, allergies, hepatocellular carcinoma, osteoporosis, renal fibrosis and cancer.

* * * * *

2020
Bogotá, D.C.,

Doctora
Luz Clemencia de Páez
Apoderada

Oficio N°:


17239

ASUNTO:	Radicación PCT N°	10-132362
	Trámite	011
	Evento	378
	Actuación	440
	Folios	009

Con fundamento en lo previsto por el artículo 43 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica que la oposición presentada por la doctora Eliana Isaura Moreno Bohórquez, en su calidad de apoderada de Procaps S.A., reúne los requisitos formales exigidos por la ley al momento de su presentación.

En cumplimiento de lo dispuesto en la citada norma, se le concede el término de sesenta (60) días hábiles siguientes a la fecha de notificación del presente oficio, para que haga valer sus argumentaciones y presente pruebas.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única N° 10 de 2001.



JOSÉ LUIS SALAZAR LÓPEZ
Director de Nuevas Creaciones (C).

04 NOV. 2011

El anterior oficio fue notificado por fijación en lista de fecha, _____.

2020211 